STOCK TITAN

Femasys Q3 2026 loss widens to $4.56M as sales fall

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Femasys Inc. (FEMY) reported third-quarter and nine-month results: sales for the three months ended September 30, 2026 were $404,597, compared with $729,394 a year earlier, while net loss was $4,564,815 versus $4,194,821. For the first nine months, sales were $1,161,313 versus $1,479,926, and net loss was $8,187,810 versus $14,677,582.

Cash and cash equivalents were $23,913,946 at September 30, 2026. Operating activities used $12,896,701 during the first nine months. Femasys said the cash on hand was expected to fund planned operations, capital requirements and other obligations for at least the twelve-month period following issuance of the statements.

The August 2026 private placement generated $29,999,580 in gross proceeds before $2,627,782 in transaction costs, with net proceeds of $27,371,798. Femasys issued 5,013,559 common shares and warrants; full cash exercise of the warrants could provide up to $55.3 million.

2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 3 points

How the balance works

Positive

  • Moderate pointNine-month net loss narrowed to $8,187,810 from $14,677,582.
  • Moderate pointNine-month operating cash use was $12,896,701, versus $14,505,325 in 2025.

Negative

  • Moderate pointQuarterly sales were $404,597, versus $729,394 a year earlier.
  • Minor pointNine-month sales were $1,161,313, versus $1,479,926 in 2025.
  • Minor pointThird-quarter net loss widened to $4,564,815 from $4,194,821.

Filing Explained

Noteholders seek about $3.1 million plus interest and fees; Femasys recorded no accrual, saying a loss was not considered probable.

At September 30, 2026, Femasys had about $9.4 million of nominal capacity remaining under its at-the-market prospectus, but the company says the baby-shelf limit could make permitted sales substantially lower.

That rule limits primary shelf sales over a 12-month period to one-third of public float when float is below $75 million, with earlier sales reducing remaining capacity; Femasys reported selling 31,195 shares for about $353,000 through the ATM in the first nine months. Separately, the company had the right, but not the obligation, to sell up to $10 million in shares under its Any Market Purchase Agreement through December 31, 2026. It reported no sales under that agreement as of September 30, 2026.

On September 2, 2026, holders of part of Femasys’s 2025 notes filed a motion for summary judgment in lieu of complaint, alleging the August financing triggered repayment under the notes and seeking about $3.1 million, plus interest and attorneys’ fees. Femasys says the allegations are without merit and that it will defend the action. The company recorded no accrual because it did not consider a loss probable and could not estimate any reasonably possible loss.

Three-month sales $404,597 Three months ended September 30, 2026; $729,394 in 2025.
Nine-month sales $1,161,313 Nine months ended September 30, 2026; $1,479,926 in 2025.
Three-month net loss ($4,564,815) Three months ended September 30, 2026; ($4,194,821) in 2025.
Nine-month net loss ($8,187,810) Nine months ended September 30, 2026; ($14,677,582) in 2025.
Cash and cash equivalents $23,913,946 As of September 30, 2026.
Net cash used in operating activities ($12,896,701) Nine months ended September 30, 2026; ($14,505,325) in 2025.
August 2026 financing gross proceeds $29,999,580 Before transaction costs of $2,627,782.
Potential warrant exercise proceeds Up to $55.3 million Potential additional proceeds upon full cash exercise of the warrants issued in the August 2026 financing.
PIK interest financial
"PIK interest on November 2025 Notes"
Payment-in-kind (PIK) interest is interest on a loan or bond that is paid by adding to the borrower’s debt rather than by handing over cash; think of it as paying rent by giving an IOU that increases the total owed instead of using money now. Investors care because PIK raises short-term cash for the borrower but increases future risk — the lender receives a larger, deferred payment and assumes more credit and timing uncertainty.
baby-shelf limitations regulatory
"the amount the Company was authorized to sell was subject to baby-shelf limitations"
volume-weighted average price (VWAP) financial
"the volume-weighted average price of the Company’s common stock"
Volume-weighted average price (VWAP) is the average price of a security over a trading period where each trade’s price is weighted by how many shares were traded, so larger trades pull the average more than tiny ones. Investors and traders use VWAP as a benchmark to judge whether a trade was executed at a favorable price—similar to checking whether you paid more or less than the typical price when most people were buying or selling.
Level 3 inputs financial
"using Level 3 inputs"
Level 3 inputs are the assumptions and estimates a company uses to value assets or liabilities when there is no observable market price, so the valuation relies heavily on internal models and judgment. For investors this matters because these valuations are less verifiable and more subject to error or bias—like estimating the value of a unique vintage car versus checking a price list—and can materially affect reported earnings and balance-sheet strength.
pre-funded warrants financial
"pre-funded warrants to purchase up to 4,361,440 shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
two-class method financial
"requires the use of the two-class method"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did FEMY raise in its August 2026 financing?

FEMY reported $29,999,580 in gross proceeds before $2,627,782 in transaction costs; net proceeds were $27,371,798.

What were FEMY’s sales and net loss in Q3 2026?

For the three months ended September 30, 2026, sales were $404,597 and net loss was $4,564,815. The comparable 2025 figures were $729,394 in sales and a $4,194,821 net loss.

What conditions apply to FEMY’s August 2026 milestone warrants?

The milestone warrants become exercisable on August 10, 2027; satisfaction of the Milestone Conditions is not required for exercisability and may only accelerate expiration. Those conditions include at least $1.5 million in U.S. revenue in any fiscal quarter, specified market-price tests—including a volume-weighted average price at or above 130% of the exercise price for at least 20 trading days in a 30-trading-day period—and an effective resale registration statement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q
 
(Mark One)
 
☑
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended September 30, 2026
 
OR
 
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from ____________to____________
 
Commission file number: 001-40492.
 
Femasys Inc.
 
(Exact Name of Registrant as Specified in its Charter)
 
   
Delaware   11-3713499
(State or other jurisdiction of incorporation or organization)   (IRS Employer Identification No.)
 
3950 Johns Creek Court, Suite 100
Suwanee, GA
 
30024
(Address of principal executive offices)
 
(Zip Code)
 
(770) 500-3910
 
 
(Registrant’s telephone number, including area code)
 
 
 
N/A
 
 
(Former name, former address and former fiscal year, if changed since last report)
 
 
 
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
 
Trading symbol
 
Name of each exchange on which registered
Common stock, $0.001 par value
 
FEMY
 
The Nasdaq Capital Market
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐
 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
   
Large accelerated filer ☐
Accelerated filer ☐
Non-accelerated filer ☑
Smaller reporting company ☑
Emerging growth company ☑
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☑
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑
 
The Registrant had 8,656,277 shares of common stock, $0.001 par value, outstanding as of November 12, 2026.
 

1

 
   
 
TABLE OF CONTENTS
 
    Page
     
Part I. Financial Information
Item 1
Condensed Financial Statements
5
 
Condensed Balance Sheets as of September 30, 2026 and December 31, 2025 (unaudited)
5
 
Condensed Statements of Operations for the Three and Nine Months Ended September 30, 2026 and 2025 (unaudited)
7
 
Condensed Statements of Stockholders’ Equity for the Three and Nine Months Ended September 30, 2026 and 2025 (unaudited)
8
 
Condensed Statements of Cash Flows for the Nine Months Ended September 30, 2026 and 2025 (unaudited)
9
 
Notes to Condensed Financial Statements (unaudited)
10
Item 2 Management’s Discussion and Analysis of Financial Condition and Results of Operations 28
Item 3
Quantitative and Qualitative Disclosures About Market Risk
41
Item 4
Controls and Procedures
42
 
Part II. Other Information
Item 1
Legal Proceedings
43
Item 1A
Risk Factors
43
Item 2
Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities
45
Item 3
Defaults Upon Senior Securities
45
Item 4
Mine Safety Disclosures
45
Item 5
Other Information
45
Item 6
Exhibits
46
SIGNATURES
 
 
2

Table of Contents
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
 
This Quarterly Report on Form 10-Q contains forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning:
 
•
our ability to obtain additional financing to fund commercialization of our products and fund our operations;
 
•
our ability to obtain additional financing to fund the U.S. clinical development of our U.S. product candidate, FemBloc® permanent birth control;
 
•
our ability to obtain U.S. Food and Drug Administration (FDA) approval for our U.S. product candidate, FemBloc for permanent birth control;
 
•
our ability to successfully grow sales of FemaSeed® intratubal insemination in the U.S.;
 
•
our ability to successfully grow sales internationally;
 
•
estimates regarding the total addressable market for our products and U.S. product candidate;
 
•
competitive companies and technologies in our industry;
 
•
our business model and strategic plans for our products, U.S. product candidate, technologies and business, including our implementation thereof;
 
•
commercial success and market acceptance of our products and U.S. product candidate;
 
•
our ability to achieve and maintain adequate levels of coverage or reimbursement for FemBloc or any future product candidates, and for our products we seek to commercialize;
 
•
our ability to accurately forecast customer demand for our products and U.S. product candidate, and manage our inventory;
 
•
our ability to build, manage, and maintain our direct sales and marketing organization, and to market and sell our FemaSeed intratubal insemination product, FemBloc permanent birth control system, and women-specific medical product solutions in markets in and outside of the United States;
 
•
our ability to establish, maintain, grow or increase sales and revenues;
 
•
our expectations about market trends;
 
•
our ability to continue operating as a going concern;
 
•
the ability of our clinical trials to demonstrate the safety and effectiveness of our U.S. product candidate, FemBloc, and other positive results;
 
•
our ability to enroll subjects in the clinical trial for our U.S. product candidate, FemBloc, in order to advance the development thereof on a timely basis;
3

Table of Contents
•
our ability to manufacture our products and U.S. product candidate, if approved, in compliance with applicable laws, regulations, and requirements and to oversee third-party suppliers, service providers and vendors in the performance of any contracted activities in accordance with applicable laws, regulations, and requirements;
 
•
our ability to hire and retain our senior management and other highly qualified personnel;
 
•
FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets;
 
•
the timing or likelihood of regulatory filings and approvals or clearances;
 
•
our ability to establish and maintain intellectual property protection for our products and U.S. product candidate and our ability to avoid claims of infringement; and
 
•
the volatility of the trading price of our common stock.
 
The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of known and unknown risks, uncertainties and assumptions, including those described under the sections in this Quarterly Report on Form 10-Q entitled “Risk Factors” and “Management's Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2026 (“Annual Report”) and this Quarterly Report on Form 10-Q. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q, including our Annual Report, and have filed with the SEC as exhibits hereto completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Section 27A of the Securities Act of 1933, as amended (the “Securities Act”).
 
4

Table of Contents
PART I. FINANCIAL INFORMATION
 
ITEM 1.
Condensed Financial Statements
 
FEMASYS INC.
Condensed Balance Sheets
(unaudited)
 
         
Assets  September 30,
2026
   December 31,
2025
 
Current assets:           
Cash and cash equivalents
 $ 23,913,946    9,266,353 
Accounts receivable, net
   233,778    616,600 
Inventory
   6,166,371    5,740,249 
Prepaid and other current assets
   893,098    833,133 
Total current assets
   31,207,193    16,456,335 
Property and equipment, at cost:
          
Leasehold improvements
   1,238,886    1,238,886 
Office equipment
   91,610    78,155 
Furniture and fixtures
   424,586    417,876 
Machinery and equipment
   3,125,855    3,065,713 
Construction in progress
   991,124    897,885 
     5,872,061    5,698,515 
Less accumulated depreciation
   (3,991,222)    (3,802,940) 
Net property and equipment
   1,880,839    1,895,575 
Long-term assets:
          
Lease right-of-use assets, net
   952,796    1,297,121 
Intangible assets, net of accumulated amortization
   99,902    134,914 
Other long-term assets
   946,928    940,232 
Total long-term assets
   1,999,626    2,372,267 
            
Total assets
 $ 35,087,658    20,724,177 
 
(continued)
 
5

Table of Contents
FEMASYS INC.
Condensed Balance Sheets
(unaudited)
 
         
Liabilities and Stockholders’ Equity  September 30,
2026
   December 31,
2025
 
Current liabilities:           
Accounts payable
 $ 1,958,546    1,830,124 
Accrued expenses
   855,377    1,265,773 
Note payable
   292,229     — 
Clinical holdback – current portion
   29,250    52,644 
Operating lease liabilities – current portion
   465,960    487,624 
Total current liabilities
   3,601,362    3,636,165 
Long-term liabilities:
          
Clinical holdback – long-term portion
   58,179    52,370 
Convertible notes payable, net
   3,717,653    3,178,864 
Conversion option liability
   —    2,014,000 
Warrants liabilities
   —    4,943,000 
Operating lease liabilities – long-term portion
   682,302    1,030,476 
Total long-term liabilities
   4,458,134    11,218,710 
Total liabilities
   8,059,496    14,854,875 
Commitments and contingencies   
 
    
 
 
Stockholders' equity:
          
Common stock, $0.001 par, 200,000,000 shares authorized, 8,662,139 shares issued and 8,656,277 shares outstanding as of September 30, 2026; and 2,986,116 shares issued and 2,980,254 shares outstanding as of December 31, 2025
   8,662    2,986 
Treasury stock, 5,862 common shares
   (60,000)    (60,000) 
Warrants
   19,023,695    5,246,150 
Additional paid-in capital
   162,069,759    146,506,310 
Accumulated deficit
   (154,013,954)    (145,826,144) 
Total stockholders’ equity
   27,028,162    5,869,302 
            
Total liabilities and stockholders' equity
 $ 35,087,658    20,724,177 
 
The accompanying notes are an integral part of these condensed unaudited financial statements.
 
6

Table of Contents
FEMASYS INC.
Condensed Statements of Operations
(unaudited)
 
                      
   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
    2026     2025    2026    2025 
Sales
 $ 404,597    729,394    1,161,313    1,479,926 
Cost of sales (excluding depreciation expense)
   187,496    293,838    488,538    569,275 
                      
Operating expenses:
                    
Research and development
   1,942,927    1,382,022    5,199,206    5,764,923 
Sales and marketing
   943,002    1,143,805    3,552,755    3,037,349 
General and administrative
   1,704,091    1,477,800    5,418,059    4,817,485 
Depreciation and amortization
   77,091    85,697    242,172    256,835 
Total operating expenses
   4,667,111    4,089,324    14,412,192    13,876,592 
Loss from operations
   (4,450,010)    (3,653,768)    (13,739,417)    (12,965,941) 
Other income (expense):
                    
Interest income
   85,610    17,315    155,131    53,488 
Change in fair value of Conversion Option liability
     —     —    1,732,413     — 
Change in fair value of Warrants liabilities
     —     —    4,228,000     — 
Interest expense
   (200,415)    (532,073)    (563,072)    (1,483,022) 
Other expense
     —    (26,295)    —    (286,295) 
Total other income (expense), net
   (114,805)    (541,053)    5,552,472    (1,715,829) 
Loss before income taxes
   (4,564,815)    (4,194,821)    (8,186,945)    (14,681,770) 
Income tax expense (benefit)
     —     —    865    (4,188) 
Net loss
 $ (4,564,815)    (4,194,821)    (8,187,810)    (14,677,582) 
                      
Net loss attributable to common stockholders
 $ (4,564,815)    (4,194,821)    (8,187,810)    (14,677,582) 
                      
Basic and diluted loss per share
 $ (0.53)    (2.05)    (1.59)    (9.25) 
Weighted-average common shares and pre-funded warrants outstanding, basic and diluted
   8,660,381    2,050,761    5,136,109    1,586,992 
 
The accompanying notes are an integral part of these condensed unaudited financial statements.
 
7

Table of Contents
FEMASYS INC.
Condensed Statements of Stockholders’ Equity
(unaudited)
 
                                 
                                 
                                 
                                 
                                 
                                 
 
Common stock  
Treasury
common stock
         Additional
paid-in
    Accumulated     Total
stockholders’
 
    Shares     Amount     Shares     Amount     Warrants    capital     deficit     equity  
THREE MONTHS ENDED SEPTEMBER 30, 2026
                                       
                                         
Balance at June 30, 2026
  3,023,967   $3,030    5,862   $(60,000)   $5,961,150   $147,575,906   $(149,449,139)   $4,030,947 
Issuance of common stock and warrants in connection with August 2026 financing, net of issuance costs
  5,013,559    5,014     —     —    15,203,890    12,162,894     —    27,371,798 
Exercise of pre-funded warrants
  618,751    618     —     —    (2,141,345)    2,140,743     —    16 
Share-based compensation expense
   —     —     —     —     —    190,216     —    190,216 
Net loss
   —     —     —     —     —     —    (4,564,815)    (4,564,815) 
Balance at September 30, 2026
  8,656,277   $8,662    5,862   $(60,000)   $19,023,695   $162,069,759   $(154,013,954)   $27,028,162 
                                         
NINE MONTHS ENDED SEPTEMBER 30, 2026
                                       
                                         
Balance at December 31, 2025
  2,980,254   $2,986    5,862   $(60,000)   $5,246,150   $146,506,310   $(145,826,144)   $5,869,302 
                                         
 
                                       
Issuance of common stock in connection with at-the-market offering, net of issuance costs
  31,195    31     —     —     —    342,129     —    342,160 
Issuance of common stock in payment of 2023 convertible note interest, including related parties
  3,028    3     —     —     —    47,838     —    47,841 
Issuance of common stock and warrants in connection with August 2026 financing, net of issuance costs
  5,013,559    5,014     —     —    15,203,890    12,162,894     —    27,371,798 
Exercise of pre-funded warrants
  618,751    618     —     —    (2,141,345)    2,140,743     —    16 
Conversion of November 2025 convertible notes into common stock
  5,172    5     —    —    —    32,877    —     32,882 
November 2025 Conversion Option liability and Warrants liabilities reclassification
   —    —     —     —    715,000    269,000     —    984,000 
Issuance of common stock in connection with ESPP
  4,318    5     —    —    —    15,324    —     15,329 
Share-based compensation expense
   —    —     —     —     —    552,644     —    552,644 
Net loss
   —     —     —     —     —     —    (8,187,810)    (8,187,810) 
Balance at September 30, 2026
  8,656,277   $8,662    5,862   $(60,000)   $19,023,695   $162,069,759   $(154,013,954)   $27,028,162 
 
The accompanying notes are an integral part of these condensed unaudited financial statements.
 
                                 
                                 
 

Common stock  

Treasury
common stock
       
Additional
paid-in
   
Accumulated
   
Total
stockholders’
 
   
Shares
   
Amount
   
Shares
   
Amount
   
Warrants
   
 capital
   
deficit
   
equity
 
THREE MONTHS ENDED SEPTEMBER 30, 2025
                                       
                                         
Balance at June 30, 2025
  1,628,773   $1,634    5,862   $(60,000)   $1,821,744   $137,425,075   $(137,681,018)   $1,507,435 
                                         
Issuance of common stock and warrants in connection with August 2025 financing, net of issuance costs
  521,730    522     —     —    5,833,237    1,234,935     —    7,068,694 
Exercise of pre-funded warrants
  214,619    215     —     —    (927,647)    927,861     —    429 
Share-based compensation expense
   —     —     —     —     —    174,514     —    174,514 
Net loss
   —     —     —     —     —     —    (4,194,821)    (4,194,821) 
Balance at September 30, 2025
  2,365,122   $2,371    5,862   $(60,000)   $6,727,334   $139,762,385   $(141,875,839)   $4,556,251 
                                         
NINE MONTHS ENDED SEPTEMBER 30, 2025
                                       
                                         
Balance at December 31, 2024
  1,167,797   $1,174    5,862   $(60,000)   $1,860,008   $127,701,497   $(127,198,257)   $2,304,422 
                                         
                                         
Issuance of common stock in connection with at-the-market offering, net of issuance costs
  190,597    190     —     —     —    5,323,164     —    5,323,354 
Issuance of common stock in connection with June 2025 financing, net of issuance costs
  264,314    264     —     —     —    3,700,047     —    3,700,311 
Issuance of warrants in connection with June 2025 financing
   —     —     —     —    56,035    (56,035)     —     — 
Issuance of common stock and warrants in connection with August 2025 financing, net of issuance costs
  521,730    522     —     —    5,833,237    1,234,935     —    7,068,694 
Exercise of pre-funded warrants
  214,619    215     —     —    (927,647)    927,861     —    429 
Issuance of common stock in connection with ESPP   2,463    2    —    —    —    40,873    —    40,875 
Share-based compensation expense
   —     —     —     —     —    723,722     —    723,722 
Expiration of warrant   —    —    —    —    (94,299)   94,299    —    — 
Conversion of convertible notes into common stock   3,602    4    —    —    —    72,022    —    72,026 
Net loss
   —     —     —     —     —     —    (14,677,582)    (14,677,582) 
Balance at September 30, 2025
  2,365,122   $2,371    5,862   $(60,000)   $6,727,334   $139,762,385   $(141,875,839)   $4,556,251 
 
The accompanying notes are an integral part of these condensed unaudited financial statements.
 
8

Table of Contents
FEMASYS INC.
Condensed Statements of Cash Flows
(unaudited)
 
           
 
Nine Months Ended
September 30,
 
    2026     2025  
Cash flows from operating activities:
         
Net loss
 $(8,187,810)    (14,677,582) 
Adjustments to reconcile net loss to net cash used in operating activities:
         
Depreciation
  188,282    227,371 
Amortization
  53,890    29,464 
Change in fair value of Conversion Option liability
  (1,732,413)     — 
Change in fair value of Warrants liabilities
  (4,228,000)     — 
Amortization of right-of-use assets
  344,325    386,198 
Loss on fixed asset dispositions
  —    53,173 
Share-based compensation expense
  552,644    723,722 
PIK interest and amortization of debt issuance costs and discount
  559,084    1,173,153 
Changes in operating assets and liabilities:
         
Accounts receivable
  382,822    (83,826) 
Inventory
  (426,122)    (2,737,651) 
Prepaid and other assets
  288,245    283,382 
Accounts payable
  58,330    656,403 
Accrued expenses
  (362,555)    (122,588) 
Lease liabilities
  (369,838)    (392,850) 
Other liabilities
  (17,585)    (23,694) 
Net cash used in operating activities
  (12,896,701)    (14,505,325) 
           
Cash flows from investing activities:
         
Purchases of property and equipment
  (106,050)    (385,167) 
Acquisition of patents
  (16,282)    (48,216) 
Net cash used in investing activities
  (122,332)    (433,383) 
           
Cash flows from financing activities:
         
Proceeds from issuance of common stock in June 2025 financing
   —    4,510,001 
Issuance costs for June 2025 financing
   —    (804,940) 
Proceeds from at-the-market sales of common stock
  352,922    5,496,791 
Issuance costs for at-the-market sales of common stock
  (10,588)    (164,904) 
Proceeds from common stock issued through ESPP
  15,329    40,875 
Proceeds from the issuance of common stock, accompanying warrants and pre-funded warrants in August 2025 financing
   —    7,998,826 
Issuance costs for August 2025 financing
   —    (930,132) 
Proceeds from the issuance of common stock, accompanying warrants and pre-funded warrants in August 2026 financing
  29,999,580     — 
Issuance costs for August 2026 financing
  (2,627,782)     — 
Proceeds from the exercise of pre-funded warrants
  16    429 
Repayment of note payable
  (62,851)    (90,961) 
Net cash provided by financing activities
  27,666,626    16,055,985 
Net change in cash and cash equivalents
  14,647,593    1,117,277 
           
Cash and cash equivalents:
         
Beginning of period
  9,266,353    3,451,761 
End of period
 $23,913,946    4,569,038 
           
Supplemental cash flow information
         
Cash paid for:
         
Interest
 $3,988    4,057 
Income taxes
  5,550    6,006 
Non-cash investing and financing activities:
         
Property and equipment costs included in accounts payable
  67,496    53,065 
Acquisition of patents included in accounts payable
  2,596    45,371 
Issuance of warrants for underwriter commission in connection with June 2025 financing
   —    56,035 
Issuance of warrants for underwriter commission in connection with August 2025 financing
   —    97,612 
Deferred offering costs reclassified to additional paid-in capital
  174    13,283 
Conversion of November 2025 convertible notes into common stock
  76,452     — 
Conversion of November 2023 convertible notes into common stock
   —    85,000 
Payment of November 2023 convertible note interest in common stock
  47,841     — 
Prepaid insurance financed with promissory notes
  355,080    276,489 
 
The accompanying notes are an integral part of these condensed unaudited financial statements.
 
9

Table of Contents
FEMASYS INC.
Condensed Notes to Financial Statements
(unaudited)
 
(1)
Organization, Nature of Business, and Liquidity
 
Organization and Nature of Business
 
Femasys Inc. (the “Company” or “Femasys”) was incorporated in Delaware on February 19, 2004 and is headquartered in Suwanee, Georgia. The Company is a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, with a broad patent-protected portfolio of disruptive, accessible, in-office therapeutic and diagnostic products. The Company is a U.S. manufacturer that has received global regulatory approvals for its product portfolio, which is currently being commercialized in the U.S. and key international markets. The Company’s suite of products and U.S. product candidate address what the Company believes are multi-billion dollar global market segments in which there has been little advancement for many years, helping women avoid pharmaceutical solutions, implants and surgery that can be expensive and expose women to harm.
 
Basis of Presentation
 
The Company has prepared the accompanying condensed financial statements pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to these rules and regulations. These condensed financial statements should be read in conjunction with the Company’s audited financial statements and footnotes related thereto for the year ended December 31, 2025 included in our Annual Report on Form 10-K filed with the SEC on March 31, 2026 (the Annual Report). There have been no material changes to the Company’s significant accounting policies described in Note 2 to the financial statements included in the Annual Report.
 
10

Table of Contents
FEMASYS INC.
Condensed Notes to Financial Statements
(unaudited)
 
In the opinion of management, the unaudited condensed financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Company’s financial position and the results of its operations and cash flows at the dates and for the periods presented. The results of operations for such interim periods are not necessarily indicative of the results expected for the full year.
 
Use of Estimates
 
The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. Estimates for these and other items are subject to change and are reassessed by management in accordance with U.S. GAAP. Actual results could differ from those estimates.
 
Liquidity
 
As of September 30, 2026, the Company had cash and cash equivalents of $23,913,946.
 
The Company has incurred recurring losses and generated a net loss of $8.2 million for the nine months ended September 30, 2026. The Company expects to continue investing in the commercialization of FemaSeed and other products and in the continued clinical development of FemBloc. Accordingly, the Company expects to incur operating losses and utilize cash in support of these activities.
 
The Company believes that its cash and cash equivalents as of September 30, 2026 will provide sufficient liquidity to fund its planned operations, capital requirements, and other obligations for at least the twelve-month period following the issuance of these condensed financial statements.
 
Reverse Stock Split
 
On June 5, 2026, the Company filed an amendment to its Eleventh Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company’s common stock, par value $0.001 per share, at a ratio of 1-for-20 (the “Reverse Stock Split”). The Reverse Stock Split did not change the authorized number of shares of the Company’s common stock. The Amendment was authorized by the stockholders of the Company at the Company’s special meeting of stockholders held on April 29, 2026.
 
Pursuant to the Amendment, on June 5, 2026, every 20 shares of common stock were automatically converted into one share of common stock, without any change in par value per share. No fractional shares were issued, and any fractional shares resulting from the Reverse Stock Split were rounded up to the nearest whole share at the Depository Trust Company (DTC) participant level.
 
The Reverse Stock Split applied to the Company’s outstanding warrants, stock options and restricted stock units. The number of shares of common stock into which these outstanding securities are convertible or exercisable was adjusted proportionately as a result of the Reverse Stock Split. The exercise prices of outstanding warrants and stock options were also proportionately adjusted in accordance with the terms of those securities and the Company’s equity incentive plans. The number of shares of common stock reserved for future issuance under the Company’s 2021 Equity Incentive Plan was also proportionately adjusted.
 
The Reverse Stock Split became effective at 8:40 a.m. Eastern Time on June 5, 2026, and the Company’s common stock began trading on a split-adjusted basis at the opening of trading on June 8, 2026. All shares of common stock, including common stock underlying warrants, stock options and restricted stock units, as well as all conversion ratios, exercise prices, conversion prices and per share information in the condensed financial statements have been retroactively adjusted to reflect the 1-for-20 Reverse Stock Split for all periods presented.
 
11

Table of Contents
FEMASYS INC.
Condensed Notes to Financial Statements
(unaudited)
 
Recently Issued Accounting Pronouncements – Recently Adopted
 
In November 2024, the FASB issued ASU 2024-04, Debt—Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments. The ASU clarifies the accounting for induced conversion of convertible debt instruments and requires entities to recognize the fair value of any incremental consideration provided to induce conversion as expense. ASU 2024-04 is effective for the Company’s annual reporting periods beginning after December 15, 2025. The Company adopted the ASU on January 1, 2026, and it did not have an impact on the Company’s financial statements.
 
Recently Issued Accounting Pronouncements – Not Yet Adopted
 
In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (Subtopic 220-40). The standard requires public business entities to disclose additional information about specific expense categories included in relevant income statement captions, including purchases of inventory, employee compensation, depreciation, amortization of intangible assets, and certain other expenses. ASU 2024-03 is effective for the Company’s annual reporting periods beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The ASU may be applied either with a prospective or a fully retrospective transition method. The Company will adopt the ASU beginning January 1, 2027 and is currently evaluating the impact of the adoption on its interim financial statements and disclosures.
 
In September 2025, the FASB issued ASU 2025-06, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. The amendments modernize the accounting guidance for costs incurred to develop software for internal use, including removing the project-stage framework and revising the criteria for determining when capitalization of software development costs should begin. The ASU is effective for the Company’s annual and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company will adopt the ASU beginning January 1, 2028 and is currently evaluating the impact of the adoption on its interim financial statements and disclosures.
 
In September 2025, the FASB issued ASU 2025-07, Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract. The amendments refine the scope of derivative accounting under Topic 815, including the application of the scope exception for certain contracts with underlying variables based on the operations or activities of one of the parties to the contract. The ASU is effective for the Company’s annual and interim reporting periods beginning after December 15, 2026. Early adoption is permitted. The Company will adopt the ASU beginning January 1, 2027 and is currently evaluating the impact of the adoption on its interim financial statements and disclosures.
 
In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements. The amendments clarify the applicability of the interim reporting guidance in Topic 270 and improve the navigability of interim disclosure requirements by providing a more comprehensive listing of disclosures required in interim financial statements. The ASU is effective for the Company’s interim periods in annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The ASU may be applied either with a prospective method or a fully retrospective method of transition. The Company will adopt the ASU beginning January 1, 2028 and is currently evaluating the impact of the adoption on its interim financial statements and disclosures.
 
In December 2025, the FASB issued ASU 2025-12, Codification Improvements, which makes amendments to various Topics within the Accounting Standards Codification, including Topic 260, Earnings Per Share. The ASU is effective for the Company’s annual and interim reporting periods beginning after December 15, 2026, with early adoption permitted. The Company will adopt the ASU beginning January 1, 2027 and is currently evaluating the impact of the adoption on its interim financial statements and disclosures.
 
No other new accounting pronouncements issued or effective have had, or are expected to have, a material impact on the Company’s financial statements.
 
(2)
Fair Value of Financial Instruments
 
The Company applies a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories:
 
Level 1 – Valuation is based upon quoted prices for identical instruments traded in active markets.
 
Level 2 – Valuation is based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model‑based valuation techniques for which all significant assumptions are observable in the market.
 
Level 3 – Valuation is generated from model‑based techniques that use significant assumptions not observable in the market. These unobservable assumptions reflect the Company’s own estimates of assumptions market participants would use in pricing the asset or liability.
 
Certain of the Company’s financial instruments, including cash and cash equivalents, accounts receivable and other liabilities approximate their fair value because of the short‑term maturity of these financial instruments.
 
12

Table of Contents
The fair value of the Any Market Purchase Agreement (“AMPA,” see Note 10) was measured as of September 30, 2026 using Level 3 inputs and was determined to be de minimis.
 
On April 29, 2026, following shareholder approval permitting the issuance of shares underlying the Conversion Option and Warrants in excess of the Nasdaq 19.99% limitation (see Note 9b), the limitation that had previously prevented the Conversion Option and Warrants from meeting the equity classification criteria under ASC 815-40 was eliminated. Accordingly, the Company reassessed the instruments under ASC 815-40 and determined that the Conversion Option and Warrants met the criteria for equity classification. The derivative liabilities were reclassified to additional paid-in capital and warrant equity, respectively, at their fair values on the April 29, 2026 reclassification date. Following the reclassification, the instruments are no longer remeasured at fair value on a recurring basis. Prior to their reclassification to equity on April 29, 2026, the Conversion Option liability and Warrants liabilities were classified within Level 3 of the fair value hierarchy.
 
During the nine months ended September 30, 2026, the Company recognized changes in the fair values of the Conversion Option and Warrants liabilities resulting from the March 19, 2026 modification and subsequent remeasurement through the April 29, 2026 reclassification date. In connection with the March 19, 2026 modification, the Company also recognized the Series D-1 Warrants at fair value upon issuance. The changes in fair value were recognized as gains in other income (expense), net in the condensed statements of operations. Activity through the April 29, 2026 reclassification date is summarized below:
 
         
    Fair Value of
Conversion Option
Liability
    Fair Value of
Warrants Liabilities
 
Balance at December 31, 2025
 $ 2,014,000  $ 4,943,000 
Change in fair value other than modification
   (1,112,413)     (4,084,000) 
Change in fair value related to March 19, 2026 modification
   (401,000)     (1,801,000) 
Issuance of Series D-1 Warrants
   —      2,202,000 
Conversion of convertible note
   (12,587)       —  
Change in fair value other than modification on April 29, 2026
   (219,000)     (545,000) 
Reclassification to equity upon April 29, 2026 shareholder approval
   (269,000)     (715,000) 
Balance at April 29, 2026 reclassification
  $ —   $ — 
 
The fair values of the Conversion Option liability and Warrants liabilities were estimated using the Black-Scholes option pricing model with Level 3 inputs, with the following assumptions immediately prior to the reclassification on April 29, 2026:
 
         
    Conversion
Option
Liability
    Warrants
Liabilities
 
Expected term (in years)
  2.52     2.52  
Risk‑free interest rate
 3.80 %  3.80 %
Dividend yield
   — %    — %
Expected volatility
  30.00 %   30.00 %
Exercise price
 $14.66  $ 11.60 - $22.00  
Stock price
 $7.40  $7.40
             
Black-Scholes value
 $0.26    $ 0.04 - $0.56  
 
The valuations of the Conversion Option liability and Warrants liabilities prior to reclassification in April 2026 (see Note 9b) were calibrated such that the aggregate change in fair value of the outstanding Conversion Option and Warrants equaled the fair value of the Series D-1 Warrants issued on the modification date. This calibration resulted in an expected volatility assumption of 30%, which was also the volatility assumption used to value the Conversion Option liability and Warrants liabilities as of April 29, 2026. If the Company used the historical volatility of its common stock as the expected volatility assumption, the estimated value of the Conversion Option liability and Warrants liabilities would be higher. The expected terms of the Conversion Option and Warrants as of April 29, 2026, were consistent with the terms used as of December 31, 2025, as adjusted for additional time lapsed, which were based on the Company’s option to mandate conversion of the Notes upon achieving certain milestones (see Note 9b) as well as the expectation that the Warrants will be exercised upon a significant increase in the price of the Company’s common stock. If the Company used the contractual term of the Conversion Option and Warrants as the expected term, the estimated value of the Conversion Option liability and Warrants liabilities would be higher.
 
13

Table of Contents
We review the fair value hierarchy classification of our applicable assets and liabilities on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification for certain financial assets or liabilities. During the quarter ended September 30, 2026, there were no transfers between Level 1, Level 2 and Level 3. The pre-funded warrants, common warrants and milestone warrants issued in the August 2026 financing are classified in stockholders’ equity and are not remeasured at fair value subsequent to issuance (see Note 10).
 
The carrying amounts of cash and cash equivalents, accounts receivable, customer deposits, accounts payable and accrued expenses approximate fair value due to their short-term nature. As of September 30, 2026, the fair value of the 2025 Notes (excluding the Conversion Option, see Note 9b), calculated using a discounted cash flow analysis with Level 3 inputs, was approximately $3.8 million.
 
(3)
Cash and Cash Equivalents
 
As of September 30, 2026 and December 31, 2025, certificates of deposit and short-term U.S. Treasury bills included in cash and cash equivalents on the balance sheets were $22,113,877 and $7,110,655, respectively. Short-term U.S. Treasury bills and certificates of deposit were classified as Level 1 and Level 2 in the fair value hierarchy, respectively. The Company considers all highly liquid investments with an initial maturity of three months or less when purchased to be cash equivalents.
 
14

Table of Contents
FEMASYS INC.
Condensed Notes to Financial Statements
(unaudited)
 
(4)
Inventories
 
Inventory, stated at lower of cost or net realizable value, consisted of the following:
 
         
   September 30,
2026
   December 31,
2025
 
Materials
 $ 1,862,615    2,060,521 
Work in progress
   1,175,384    1,266,542 
Finished goods
   3,128,372    2,413,186 
Inventory
 $ 6,166,371    5,740,249 
 
(5)
Accrued Expenses
 
Accrued expenses included the following:
 
         
   September 30,
2026
    December 31,
2025
 
Incentive and other compensation costs
 $ 400,636    870,910 
Clinical trial costs
   287,392    259,293 
Director fees
   71,250    71,250 
Other
   96,099    64,320 
Accrued expenses
 $ 855,377    1,265,773 
 
(6)
Revenue Recognition
 
Revenue is recognized upon shipment of our goods based upon contractually stated pricing at standard payment terms typically ranging from 30 to 60 days. All revenue is recognized at a point in time. As of September 30, 2026, there were no unsatisfied performance obligations.
 
The majority of products sold directly to U.S. customers are shipped via common carrier, and the customer pays for shipping and handling and assumes control at Free on Board (FOB) shipping point. Products shipped to our international distributors are in accordance with their respective agreements; however, the shipping terms are generally EX-Works, reflecting that control is assumed by the distributor at the shipping point. Returns are accepted only with prior authorization from the Company. Items to be returned must be in original unopened cartons and are subject to a 30% restocking fee. Throughout the periods presented, the Company has not had a history of significant returns.
 
The following table summarizes our sales by geographic region:
 
                      
   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
Primary geographical markets  2026    2025   2026   2025 
U.S.
 $ 347,039    336,594    1,038,997    1,015,168 
International
   57,558    392,800    122,316    464,758 
Total
 $ 404,597    729,394    1,161,313    1,479,926 
 
15

Table of Contents
FEMASYS INC.
Condensed Notes to Financial Statements
(unaudited)
 
(7)
Commitments and Contingencies
 
Legal Claims
 
On September 2, 2026, Iroquois Master Fund, Ltd. and Iroquois Capital Investment Group LLC, holders of a portion of the 2025 Notes, filed a motion for summary judgment in lieu of complaint against the Company in the Supreme Court of the State of New York, County of New York. The plaintiffs allege that the Company’s August 7, 2026 Securities Purchase Agreement (which closed on August 10, 2026) constituted a Fundamental Transaction under the 2025 Notes, triggering a repayment obligation, and seek approximately $3.1 million, plus prejudgment interest and attorneys’ fees. The Company believes the allegations are without merit and intends to defend the action vigorously. The Company has not recorded an accrual as of September 30, 2026, because a loss is not considered probable, and it cannot estimate a range of reasonably possible loss, if any.
 
(8)
Notes Payable
 
 AFCO Credit Corporation (AFCO)
 
In July 2025, the Company executed a promissory note with AFCO to finance certain insurance premiums totaling $367,450, requiring the Company to pay $31,672 as a down payment and make monthly installment payments. The annual interest rate was 7.44% and the monthly installment was $31,672, which represented principal and interest. The note was paid in full without penalty in November 2025.
 
In July 2026, the Company executed a promissory note with AFCO to finance certain insurance premiums totaling $388,500, requiring the Company to pay $33,419 as a down payment and make monthly installment payments. The annual interest rate is 6.99% and the monthly installment is $33,419, which represents principal and interest.
 
As of September 30, 2026, and December 31, 2025, there were principal balances of $292,229 and $0 on the AFCO note in the accompanying balance sheets, respectively. Interest expense in connection with the AFCO promissory note was $3,988 for the three and nine months ended September 30, 2026, and $4,057 for the three and nine months ended September 30, 2025.
 
(9)
Convertible Notes with Warrants
 
(a)
Convertible Notes with Warrants (November 2023 Financing)
 
On November 21, 2023, the Company issued (i) senior unsecured convertible notes (“Notes”) in an aggregate principal amount of $6,850,000 (“2023 Notes”), convertible into shares of common stock at a conversion price of $23.60 per share, (ii) Series A Warrants to purchase up to an aggregate of 290,256 shares of common stock at an exercise price of $23.60 per share, and (iii) Series B Warrants, together with the Series A Warrants and the convertible notes, to purchase up to an aggregate of 290,256 shares of common stock at an exercise price of $29.50 per share. The financing resulted in aggregate gross proceeds of $6,850,000, before $525,144 of issuance costs.
 
The 2023 Notes accrued interest at a rate of 6.0% per annum, payable annually, in cash or shares of common stock at the Company’s option. In November 2025, the Company paid $360,000 in accrued interest in 22,785 shares of common stock. In April 2026, the remaining $47,841 in accrued interest was paid in 3,028 shares of common stock.
 
As noted above, the 2023 Notes were convertible into shares of common stock at the election of the holder at any time at an initial conversion price of $23.60. The conversion feature did not meet the requirements for separate accounting and was not accounted for as a derivative instrument. In April 2025, $85,000 of convertible notes were converted into 3,602 shares of common stock. The 2023 Notes matured on November 21, 2025, and were repaid in full by the Company with proceeds from the November 2025 Financing discussed below. No gain or loss was recorded upon repayment of the 2023 Notes.
 
Warrants
 
The Series A Warrants are exercisable immediately and expire five years from the date of issuance. The Company has the right to call the exercise of the Series A Warrants if the closing price of the common stock exceeds 200% of the Series A Exercise Price for 10 consecutive trading days and the daily dollar trading volume of the common stock exceeds $1,000,000 per day during the same period and certain equity conditions are satisfied.
 
16

Table of Contents
FEMASYS INC.
Condensed Notes to Financial Statements
(unaudited)
 
The Series B Warrants expired in November 2024.
 
The Series A Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise. As of September 30, 2026, no Series A Warrants have been exercised.
 
For the three months ended September 30, 2025, the Company recognized total interest expense of $532,073, including coupon interest expense on the 2023 Notes of $101,475, amortization of debt discount and issuance costs on the 2023 Notes of $426,541, and AFCO note payable interest expense of $4,057. For the nine months ended September 30, 2025, the Company recognized total interest expense of $1,483,022, including coupon interest expense on the 2023 Notes of $305,812, amortization of debt discount and issuance costs on the 2023 Notes of $1,173,153, and AFCO note payable interest expense of $4,057.
 
(b)
Convertible Notes with Warrants (November 2025 Financing)
 
In November 2025, the Company issued (i) senior secured convertible notes (“2025 Notes”) in an aggregate principal amount of $12,000,000, convertible into 818,544 shares of common stock at a conversion price of $14.66 per share, (ii) Series A-1 Warrants to purchase up to an aggregate of 818,937 shares of common stock at an exercise price of $16.20 per share, subject to adjustments, (iii) Series B-1 Warrants to purchase an aggregate of 818,937 shares of common stock at an exercise price of $18.40 per share, subject to adjustments, and (iv) Series C-1 Warrants to purchase an aggregate of 818,937 shares of common stock at an exercise price of $22.00 per share, subject to adjustments (Series A-1 Warrants, Series B-1 Warrants and Series C-1 Warrants are collectively the “Warrants”). The financing resulted in aggregate gross proceeds of $12,000,000, before $718,528 of issuance costs.
 
The 2025 Notes accrue interest at a rate of 8.5% per annum, payable annually in kind by increasing the principal balance outstanding. The Company granted a security interest in substantially all of its assets to the holders of the 2025 Notes. The 2025 Notes mature in November 2035. The Company has a call option where it may voluntarily redeem the 2025 Notes after seven and one-half years from Note issuance at 112% of the then-outstanding principal.
 
The 2025 Notes are convertible into shares of common stock at the election of the holder at any time (the “Conversion Option”) at an initial conversion price of $14.66 (“Conversion Price”). The Conversion Price is adjustable proportionally for certain events, including stock splits, reverse stock splits and stock dividends (each a “Share Combination Event”). Additionally, prior to the March 2026 modification discussed below, upon a Share Combination Event, the Conversion Price would also have been further adjusted to the lowest dollar volume-weighted average price (“VWAP”) of the Company’s common stock during the five-day period following any Share Combination Event, but only if the Conversion Price, after the standard proportional adjustment, was higher than the market price.
 
The Company may require conversion of the 2025 Notes, in whole or in part, if at any time (i) a Registration Statement is effective, (ii) for the immediately preceding thirty (30) consecutive trading days, the VWAP has exceeded 450% of the then-effective Conversion Price on each such trading day, (iii) the total daily trading volume of the common stock is at least $1,500,000, and (iv) certain equity conditions are satisfied (effective registration statement is available and sufficient authorized shares are available, among other conditions). The holders of the 2025 Notes may require prepayment of principal and accrued interest upon certain Events of Default (failure to timely pay amounts owed under the 2025 Notes, failure to deliver shares upon conversion of the 2025 Notes or exercise of the related Warrants, failure to maintain an effective registration statement related to the common shares underlying the 2025 Notes and related Warrants, etc.), and the Company must redeem the 2025 Notes if involuntary bankruptcy proceedings are initiated against the Company and not dismissed within 60 days or if the Company voluntarily initiates bankruptcy. Additionally, in the event of certain merger, acquisition or business combination transactions (a "Fundamental Transaction" as defined in the 2025 Notes), the Company must redeem the 2025 Notes, and if the Fundamental Transaction occurs in the first 5 years of note issuance, the redemption will include a premium.
 
17

Table of Contents
If the Company offers future rights such as convertible securities, options, or warrants to purchase common stock to common stockholders (“Purchase Rights”), the holders of the 2025 Notes are likewise entitled to receive such Purchase Rights as if the Notes were converted and the corresponding shares of common stock were outstanding.
 
During the nine months ended September 30, 2026, $76,452 of the 2025 Notes and accrued interest thereon were converted into 5,172 shares of common stock.
 
Warrants
 
The Series A-1 Warrants are exercisable immediately and expire ten years from the date of issuance. The Series B-1 Warrants are exercisable immediately and expire at the earlier of (i) the tenth anniversary of the issuance of the Warrants, or (ii) 45 days after the Company discloses two consecutive quarters of at least $3.25 million in sales. The Series C-1 Warrants are exercisable immediately and expire at the earlier of (i) the tenth anniversary of the issuance of the Warrants, or (ii) 45 days after the Company discloses FDA approval of FemBloc.
 
The exercise price of the Warrants and the related number of shares into which the Warrants are exercisable are adjustable proportionally in the event of a Share Combination Event. Additionally, similar to the Conversion Option in the 2025 Notes and prior to the March 2026 modification discussed below, upon a Share Combination Event, the exercise prices of the Warrants would also have been further adjusted to the lowest VWAP of the Company’s common stock during the five-day period following any Share Combination Event, but only if the exercise price (after the standard proportional adjustment) was higher than the market price.
 
In the event of a Fundamental Transaction within the Company’s control, the holders of the Warrants are entitled to put the unexercised portion of the Warrants to the Company in exchange for cash at their then Black-Scholes value. If the Fundamental Transaction is outside of the Company’s control, the holders of the Warrants may receive consideration for the unexercised portion of the Warrants equal to the then Black-Scholes value in the same form (cash or equity) as other common shareholders pursuant to the Fundamental Transaction.
 
The holders of the Warrants are likewise entitled to receive Purchase Rights as if the Warrants were exercised and the corresponding shares of common stock were outstanding.
 
As of September 30, 2026, no Warrants have been exercised.
 
In March 2026, the Company modified the Conversion Option in the 2025 Notes and the exercise prices of the related Warrants to remove the market-related adjustment to the Conversion Price and exercise prices, respectively, that would otherwise have occurred upon a Share Combination Event. As consideration for this modification, the Company issued to the holders of the 2025 Notes and related Warrants new Series D-1 Warrants to purchase an aggregate number of 818,937 shares of the Company’s common stock at an exercise price of $11.60 per share. The Series D-1 Warrants expire in March 2029.
 
In April 2026, the Company’s shareholders approved the issuance of shares of common stock issuable upon conversion of the 2025 Notes and exercise of the Series A-1, B-1, C-1, and D-1 Warrants, including any issuances to directors and officers of the Company who are holders of these instruments, in excess of 19.99% of the issued and outstanding shares of common stock of the Company (to the extent that anti-dilution or price adjustment provisions in the instruments result in an effective conversion or exercise price below the Nasdaq Minimum Price).
 
The 2025 Notes and Warrants are freestanding financial instruments that are legally detachable and separately exercisable from one another. The Conversion Option within the 2025 Notes is not a freestanding financial instrument. Prior to obtaining shareholder approval on April 29, 2026, the embedded Conversion Option within the 2025 Notes and the Warrants were determined not to be indexed to the Company’s common stock due to (i) provisions permitting adjustments to the Conversion Price of the 2025 Notes and the exercise prices of the Warrants upon a Share Combination Event beyond a standard proportional adjustment (but only if the market price of the Company’s common stock was lower than the Conversion Price of the 2025 Notes or exercise prices of the Warrants) and (ii) the requirement that shareholder approval be obtained for conversions and exercises exceeding 19.99% of the Company’s outstanding shares of common stock. As a result, at issuance, the embedded Conversion Option was bifurcated from the 2025 Notes, and both the Conversion Option and the Warrants, including the Series D-1 Warrants, were recognized as derivative liabilities on the Company’s balance sheet. These derivative liabilities were subsequently remeasured at fair value at each reporting period until the equity classification criteria were satisfied on April 29, 2026. Following shareholder approval obtained on April 29, 2026 permitting the issuance of shares in excess of the Nasdaq 19.99% limitation, the Company reassessed the instruments under ASC 815-40 and determined that the Conversion Option and the Warrants met the criteria for equity classification. The Company recorded a final fair value adjustment resulting in a gain of approximately $0.8 million recognized in earnings and reclassified approximately $1.0 million of derivative liabilities to additional paid-in capital and warrant equity. Subsequent to such reclassification, the instruments are no longer remeasured at fair value.
 
The 2025 Notes are accreted to their maturity value based on the effective interest method. For the three and nine months ended September 30, 2026, the Company recognized total interest expense on the 2025 Notes of $196,427 and $559,084, respectively, consisting of paid-in-kind interest and accretion of debt discount and issuance costs. The Company also recognized AFCO note payable interest expense of $3,988 for the three and nine months ended September 30, 2026. The effective interest rate of the 2025 Notes is approximately 21.9%.
 
18

Table of Contents
See Note 2 for further detail regarding fair value of the 2025 Notes, Conversion Option and Warrants liabilities.
 
The following summarizes the carrying values of the 2025 Notes as of September 30, 2026 and December 31, 2025:
 
             
   
Stated 
Interest 
Rate

    September 30,
2026
   
December 31,
2025
 
Face value of November 2025 Notes
  8.5%   11,925,000    12,000,000 
PIK interest on November 2025 Notes
       891,473    132,139 
Less unamortized discount and debt issuance costs
       (9,098,820)    (8,953,275) 
Total Convertible Notes Payable
      $3,717,653   $3,178,864 
 
No amounts are due under the 2025 Notes until they mature in November 2035.
 
(10)
Stockholders’ Equity
 
On July 1, 2022, the Company filed a shelf registration statement to sell up to $150 million in common and preferred stock, debt securities and warrants (the “2022 Shelf”). Additionally, the Company entered into an Equity Distribution Agreement with Piper Sandler & Co. (the “Sales Agent”) and filed a related prospectus establishing an “at-the-market” facility, pursuant to which the Company may offer and sell shares of common stock from time to time through the Sales Agent. In October 2023, the Sales Agent was authorized to sell shares for aggregate proceeds of up to $16.7 million at current market prices until all shares are sold. The 2022 Shelf remained in effect until a replacement shelf registration statement was declared effective on December 9, 2025, at which time the 2022 Shelf expired. In December 2025, the Company filed a new prospectus under the replacement shelf registration statement pursuant to which it may sell up to $9.8 million under the Equity Distribution Agreement.
 
For the nine months ended September 30, 2026, the Company sold 31,195 shares of common stock for aggregate proceeds of approximately $353,000, and as of September 30, 2026, approximately $9.4 million remained available for sale pursuant to the prospectus. As of September 30, 2026, the amount the Company was authorized to sell was subject to baby-shelf limitations. Under General Instruction I.B.6 of Form S-3, companies whose public float is less than $75 million are limited in the aggregate amount of securities that may be sold on a primary basis under a shelf registration statement during any twelve-month period to no more than one-third of such company's public float. As of September 30, 2026, the Company’s public float was below $75 million, and the one-third limit constrains the total amount of common stock it is able to sell under the Equity Distribution Agreement in any twelve-month period to an amount that may be substantially less than the approximately $9.4 million of capacity nominally available under the prospectus.
 
June 2025 Financing
 
In June 2025, the Company sold 180,000 shares of common stock in an underwritten public offering at $17.00 per share. The Company also sold 84,314 shares of common stock in a separate concurrent private placement at a price of $17.00 per share to certain existing institutional stockholders and at a price of $20.40 per share to certain directors and officers. The offering resulted in aggregate gross proceeds of $4,510,001, before $804,940 of transaction costs.
 
Additionally, common warrants to purchase 5,287 shares of common stock were issued to the underwriter as a commission for services performed. The underwriter warrants are exercisable beginning December 2, 2025, have a 5-year term and an exercise price of $21.25 per share. The warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise. The warrants were valued at $56,035 using Black-Scholes assumptions. As of September 30, 2026, 5,287 underwriter warrants remain outstanding.
 
19

Table of Contents
Any Market Purchase Agreement (“AMPA”)
 
On June 30, 2025, the Company entered into an Any Market Purchase Agreement (“Purchase Agreement” or “AMPA”) with Alumni Capital LP (“Alumni”) whereby the Company has the right, but not the obligation, to sell to Alumni up to an aggregate of $10 million in shares of common stock in a series of purchases until December 31, 2026. The Company may elect that Alumni purchase up to $1 million in shares of common stock (or up to $5 million if mutually agreed) at either (i) the lowest traded price for the four previous business days, multiplied by 90% or (ii) up to the lesser of (a) $1 million in shares of common stock or (b) 100% of the average daily trading volume of common stock for the previous two business days at the lowest daily dollar volume-weighted average price, multiplied by 97%. The Company is limited to issuances to Alumni of up to 19.99% of the shares of common stock outstanding immediately prior to the execution of the Purchase Agreement. The Purchase Agreement allows the Company to raise equity on a periodic basis at its discretion depending on a variety of factors including market conditions, the trading price of the common stock, and use of proceeds for operating activities. Due to certain pricing and settlement provisions, the Purchase Agreement includes an embedded put option contract. The Company accounts for the Purchase Agreement as a derivative, with a fair value deemed de minimis. The difference between the discounted purchase price and the fair value of the shares is expensed in the period the transaction occurs as a non-cash, non-operating financing cost. See Note 2 for further detail regarding fair value of the AMPA.
 
As of September 30, 2026, no shares have been sold under the AMPA.
 
August 2025 Financing
 
On August 25, 2025, the Company entered into a securities purchase agreement pursuant to which the Company sold (i) 521,730 shares of common stock in a public offering and to certain Company officers, (ii) pre-funded warrants to purchase 587,500 shares of common stock, and (iii) common warrants to purchase 1,109,237 shares of common stock. Additionally, common warrants to purchase 22,185 shares of common stock were issued to the underwriter as compensation for services performed.
 
The pre-funded warrants, common warrants and underwriter warrants were exercisable immediately following the closing date of the offering. The pre-funded warrants have an unlimited term and an exercise price of $0.002 per share. The common warrants have a 5-year term and an exercise price of $7.20 per share, except for common warrants sold to certain Company officers, which have an exercise price of $10.31 per share. The underwriter warrants have a 5-year term and an exercise price of $9.00 per share. The offering resulted in aggregate gross proceeds of $7,998,826, before $930,132 of transaction costs.
 
The pre-funded warrants and common warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise.
 
The common stock was valued at $3,770,001, based on the Company’s stock price. The pre-funded warrants and common warrants were valued at $4,230,000 and $5,324,301, respectively, using the following Black-Scholes assumptions:
 
                         
    Pre-
funded
warrants
    Common
warrants
    Underwriter
warrants
 
Expected term (in years)
    4       4       4  
Risk‑free interest rate
    3.64 %     3.64 %     3.64 %
Dividend yield
      — %       — %       — %
Expected volatility
    90.63 %     90.63 %     90.63 %
Exercise price
  $ 0.002       $7.20 - $10.31     $ 9.00
Stock price
  $ 7.20     $7.20     $ 7.20
Black-Scholes value
  $ 7.20     $4.80 - $5.40     $ 4.40
 
The net proceeds of $7,068,694 were allocated to the common stock, pre-funded warrants and common warrants using the relative fair value method and were recorded to stockholders’ equity.
 
During the three and nine months ended September 30, 2026, 337,501 pre-funded warrants issued in the August 2025 financing were exercised on a cashless basis. As of September 30, 2026, no pre-funded warrants remained outstanding, while 648,278 common warrants and 22,185 underwriter warrants remain outstanding.
 
August 2026 Financing
 
On August 7, 2026, the Company entered into a securities purchase agreement with certain accredited investors (the “Purchasers”), pursuant to which the Company issued and sold, in a private placement that closed on August 10, 2026, (i) 5,013,559 shares of common stock, (ii) pre-funded warrants to purchase up to 4,361,440 shares of common stock, (iii) common warrants to purchase up to 9,374,999 shares of common stock and (iv) milestone warrants to purchase up to 9,374,999 shares of common stock (collectively, with the pre-funded warrants and milestone warrants, the "Warrants"). Each share of common stock or, in lieu thereof, each pre-funded warrant was sold together with one common warrant and one milestone warrant. The combined purchase price was $3.20 for each share of common stock and its accompanying common warrant and milestone warrant and $3.1999 for each pre-funded warrant and its accompanying common warrant and milestone warrant.
 
The pre-funded warrants have an exercise price of $0.0001 per share, were exercisable immediately upon closing and do not expire until exercised in full. The common warrants have an exercise price of $2.95 per share, were exercisable immediately upon closing and expire on August 10, 2029. The milestone warrants also have an exercise price of $2.95 per share, become exercisable on August 10, 2027 and expire on the earlier of (i) three years after the resale registration statement for the underlying shares is declared effective and (ii) 45 days after the Company delivers written notice that the milestone conditions have been satisfied. The “Milestone Conditions” require  (i) the Company to have reported U.S. revenue of at least $1.5 million in any fiscal quarter and (ii) the satisfaction of specified market-price and registration conditions, including that the volume-weighted average price of the Company’s common stock equal or exceed 130% of the exercise price for at least 20 trading days during a consecutive 30-trading-day period, that the volume-weighted average price on the applicable determination date equal or exceed 130% of the exercise price, and that an effective registration statement be available for resale of the underlying shares. Exercisability of the milestone warrants is not conditioned on satisfaction of the Milestone Conditions, which may only accelerate their expiration.
 
The offering resulted in aggregate gross proceeds of $29,999,580, before transaction costs of $2,627,782. The Company could receive potential additional proceeds of up to $55.3 million upon full cash exercise of the Warrants. On September 3, 2026, the Company filed a registration statement on Form S-3 to register the resale by the selling stockholders of the 5,013,559 shares of common stock issued in the private placement and the 23,111,438 shares of common stock issuable upon exercise of the Warrants.
 
The pre-funded warrants, common warrants and milestone warrants are classified as a component of permanent equity because they are freestanding financial instruments that meet the criteria for equity classification under ASC 815-40. The Warrants are legally detachable and separately exercisable from the shares of common stock with which they were issued, do not embody an obligation for the Company to repurchase its shares and permit the holders to receive a fixed number of shares of common stock upon exercise, subject to the terms of the respective warrant agreements.
 
The common stock was valued at $13,336,067 based on the Company’s stock price. The pre-funded warrants and common warrants were valued at $11,601,045 and $4,666,309, respectively, using Black-Scholes assumptions. The milestone warrants were valued at $396,158, using Black-Scholes assumptions and a Monte Carlo simulation model to determine the probability of achieving the Milestone Conditions.
 
             
    Pre-
funded
warrants
    Common
warrants
    Milestone
warrants
 
Expected term (in years)
    3       3       3  
Risk‑free interest rate
    4.2 %     4.2 %     4.2 %
Dividend yield
      — %       — %       — %
Expected volatility
    26 %     26 %     26 %
Exercise price
  $ 0.0001     $ 2.95     $ 2.95  
Stock price
  $ 2.66     $ 2.66     $ 2.66  
Black-Scholes value
  $ 2.66     $ 0.498     $ 0.498  
Probability of milestone achievement
      N/A         N/A       8.5 %
 
The net proceeds of $27,371,798 were allocated to the common stock, pre-funded warrants, common warrants and milestone warrants using the relative fair value method and were recorded to stockholders’ equity.
 
During the three and nine months ended September 30, 2026, 281,250 pre-funded warrants issued in the August 2026 financing were exercised, of which 125,000 were prepaid and closing. As of September 30, 2026, 4,080,190 pre-funded warrants, 9,374,999 common warrants and 9,374,999 milestone warrants remain outstanding.
 
20

Table of Contents
FEMASYS INC.
Condensed Notes to Financial Statements
(unaudited)
 
(11)
Equity Incentive Plans and Warrants
 
In June 2021, in connection with the IPO, the 2021 Equity Incentive Plan (2021 Plan), which was adopted by the Board of Directors in February 2021 and approved by stockholders in March 2021, became effective. As of September 30, 2026, 249,159 shares were reserved for future issuance under the Company’s stock plans for stock options and RSUs.
 
Stock-Based Awards
 
(a)
Stock Option Plans
 
Activity under the Company’s stock option plans for the nine months ended September 30, 2026 was as follows:
 
                 
    Number
of
options
    Weighted
average
exercise
price
    Weighted 
average 
remaining 
life (years)
    Aggregate
intrinsic
value
 
Outstanding at December 31, 2025
  191,552   $29.36    6.61   $92,127 
Granted
  21,280    5.27    9.69      
Forfeited
  (36,514)    26.45     —      
Outstanding at September 30, 2026
  176,318   $27.05    7.24   $ — 
                     
Vested and exercisable at September 30, 2026
                   
    102,703   $35.32    6.38   $ — 
 
The intrinsic value represents the amount by which the market price of the underlying stock at each period end reported exceeds the exercise price of the option.
 
(b)
Inducement Grants
 
Since 2023, the Company has granted inducement grants, which are stock option grants to certain employees for the right to purchase shares, which were approved by the Compensation Committee. The inducement grants vest in equal installments over four years, provided the employee remains employed by the Company on the vesting date.
 
21

Table of Contents
FEMASYS INC.
Condensed Notes to Financial Statements
(unaudited)
 
The inducement grants are summarized as follows:
 
                 
    Number
of
options
    Weighted
average
exercise
price
    Weighted 
average 
remaining 
life
(years)
    Aggregate
intrinsic
value
 
Outstanding at December 31, 2025
  6,875   $50.40    4.53   $ — 
Granted
  16,750    9.28    9.44      
Forfeited
  (6,875)    14.47     —       
Outstanding at September 30, 2026
  16,750   $24.03    8.26   $ — 
                     
Vested and exercisable at September 30, 2026
  5,000    59.40    5.41   $ — 
 
The intrinsic value represents the amount by which the market price of the underlying stock at each period end reported exceeds the exercise price of the option.
 
The Black-Scholes weighted-average assumptions for stock option awards granted to employees and nonemployees for the nine months ended September 30, 2026 were as follows:
 
                
   Nine Months Ended
September 30, 2026
 
   Employees    Nonemployees  
    2021
Plan
    Inducement
Grants
    2021
Plan
 
Options Granted
  16,000    16,750    5,280 
Fair Value of Awards
 $3.92    7.36    5.05 
Grant Price
 $4.89    9.28    6.45 
                
Expected term (in years)
  6.25    6.25    5.67 
Risk‑free interest rate
  4.28%   3.83%   4.10%
Dividend yield
   — %    — %    — %
Expected volatility
  96.89%   96.84%   97.40%
 
No options were exercised for the nine months ended September 30, 2026 under our stock option plans.
 
(c)
Restricted Stock Units (RSUs)
 
Restricted stock units were granted to employees in the first quarter of 2026 with service-based vesting conditions. Related activity during the nine months ended September 30, 2026 was as follows:
 
         
    Number
of
RSUs
    Weighted 
average 
grant
date 
fair value
 
Unvested outstanding at December 31, 2025
   —   $ — 
Granted
  71,750    10.85 
Forfeited
  (1,395)    10.40 
Unvested outstanding at September 30, 2026
  70,355   $10.86 
 
22

Table of Contents
(d)
Share-Based Compensation Expense
 
The following table shows the share-based compensation expense related to stock option, ESPP and RSU grants to employees and nonemployees by financial statement line item on the accompanying condensed statements of operations:
 
                     
   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
    2026   2025     2026     2025  
Research and development
 $33,630    65,625    98,311    270,847 
Sales and marketing
  11,529    19,047    49,982    30,034 
General and administrative
  145,057    89,842    404,351    422,841 
Total share-based compensation expense
 $190,216    174,514    552,644    723,722 
 
Share-based compensation expense by award type during the three and nine months ended September 30, 2026 and 2025 was as follows:
 
                     
   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
    2026     2025     2026     2025  
Stock options
 $95,819    159,630    313,156    708,838 
ESPP
   —    14,884    6,636    14,884 
Restricted stock units
  94,397     —    232,852     — 
Total share-based compensation expense
 $190,216    174,514    552,644    723,722 
 
As of September 30, 2026, the remaining share-based compensation expense for stock options that is expected to be recognized in future periods for employees and nonemployees is $757,749, over a weighted-average period of 2.2 years.
 
As of September 30, 2026, the remaining share-based compensation expense for RSUs that is expected to be recognized in future periods for employees is $530,970, over a weighted-average period of 2.8 years.
 
(e)
Employee Stock Purchase Plan (ESPP)
 
For the nine months ended September 30, 2026, 4,318 shares of common stock were issued under the Company’s ESPP. As of September 30, 2026, the total number of shares of common stock reserved for future awards under the ESPP was 56,405.
 
(12)
Related‑Party Transactions
 
In November 2023, the Company issued unsecured convertible notes and accompanying Series A and Series B Warrants (see Note 9a). The transaction included the issuance of a $5 million convertible note and 211,865 Series A and 211,865 Series B Warrants to PharmaCyte Biotech, Inc. (“PharmaCyte”). The interim CEO, President and Director of PharmaCyte, Joshua Silverman, served on the Company’s Board until March 2026. The Series B Warrants expired in November 2024. In November 2025, the Company paid PharmaCyte accrued interest on the convertible note of $300,000 in equity of 18,988 common shares. In November 2025, the convertible notes principal balance of $5 million was repaid at maturity. No amounts were due to PharmaCyte as of September 30, 2026.
 
23

Table of Contents
In conjunction with the June 2025 Financing (see Note 10), certain executive officers and a director of the Company purchased an aggregate of 4,904 shares of the Company’s common stock in a private placement at a price of $20.40 per share, for total gross proceeds of approximately $100,001. Other investors in the private placement purchased common stock at a discounted price of $17.00 per share. No amounts were due to or from these related parties in connection with this transaction as of September 30, 2026.
 
In conjunction with the August 2025 Financing (see Note 10), certain executive officers of the Company purchased 4,369 common shares, with a common warrant, for a combined price of $10.31. Gross proceeds from the transaction totaled approximately $45,001. The price equaled the market price of the Company’s stock on the applicable purchase date. The common warrants have a 5-year term and an exercise price of $10.31 per share. The warrants remain outstanding as of September 30, 2026. No amounts were due to or from these related parties in connection with this transaction as of September 30, 2026.
 
In the November 2025 Financing (see Note 9b), certain executive officers and directors of the Company purchased senior secured convertible notes with a combined principal balance of $175,000, convertible into common shares at a price of $14.66 per share. Additionally, in connection with the convertible notes, the officers and directors were issued 11,946 Series A-1 Warrants, 11,946 Series B-1 Warrants and 11,946 Series C-1 Warrants at exercise prices of $16.20, $18.40 and $22.00 per share, respectively. In March 2026, in connection with the modification of the Conversion Option in the 2025 Notes and the Series A-1, B-1, and C-1 Warrants, the officers and directors were issued 11,946 Series D-1 Warrants at an exercise price of $11.60 per share. As of September 30, 2026, $175,000 in convertible notes were due to the officers and directors, in addition to accrued interest of $13,346. All Series A-1, Series B-1, Series C-1 and Series D-1 warrants issued to the officers and directors remain outstanding as of September 30, 2026.
 
In connection with the August 2026 Financing (see Note 10), certain officers of the Company purchased 41,875 shares of common stock, together with accompanying common warrants to purchase 41,875 shares of common stock and milestone warrants to purchase 41,875 shares of common stock, at a combined purchase price of $3.20 per share of common stock and its accompanying warrants, for aggregate proceeds of $134,000. The officers participated in the financing on the same terms as the other purchasers of common stock. The common warrants were exercisable immediately after the closing, while the milestone warrants become exercisable on August 10, 2027, as described in Note 10. The common warrants and milestone warrants have an exercise price of $2.95 per share. The warrants remained outstanding as of September 30, 2026. No amounts were due to or from these related parties in connection with the transaction as of September 30, 2026.
 
During the nine months ended September 30, 2026, and the year ended December 31, 2025, the Company employed a family member of the CEO.
 
24

Table of Contents
FEMASYS INC.
Condensed Notes to Financial Statements
(unaudited)
 
(13)
Net Loss per Share Attributable to Common Stockholders
 
The Company presents basic and diluted earnings per share (“EPS”) data for its common stock. Basic EPS is calculated by dividing the income (loss) attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted EPS is determined by adjusting the net income (loss) attributable to common stockholders and the weighted-average number of shares outstanding for the effects of potentially dilutive common shares, including stock options, restricted stock units, warrants and convertible notes, if the effect is dilutive. Since the shares underlying the pre-funded warrants issued in the August 2025 and 2026 financings were issuable for little consideration ($0.002 and $0.0001 per share, respectively), they were considered outstanding for both basic and diluted loss per share from the date of issuance. For the three and nine months ended September 30, 2026, any unexercised pre-funded warrants were considered outstanding.
 
The Convertible Notes and certain warrants are considered participating securities under ASC 260 Earnings per Share, because they entitle holders to participate in dividends on a nonforfeitable basis. Other warrants and the Company’s stock options and restricted stock units do not have such rights and are not considered participating securities.
 
When participating securities are present, ASC 260 requires the use of the two-class method when computing basic EPS. The two-class method is an earnings allocation formula that allocates net income to common stockholders and participating securities based on their respective rights to receive dividends and share in undistributed earnings. Participating securities do not have a contractual obligation to share in losses; therefore, net losses are not allocated to participating securities.
 
For diluted EPS, the Company evaluates the potential dilutive effect of participating securities and other instruments. Stock options, restricted stock units and certain warrants are included in diluted EPS using the treasury stock method, while convertible notes are evaluated using the if-converted method, as applicable. Potential common shares are included in diluted EPS only when their effect is dilutive. For the three and nine months ended September 30, 2026 and 2025, diluted net loss per share equals basic net loss per share because the inclusion of potentially dilutive securities would have been anti-dilutive.
 
The following table sets forth the computation of the basic and diluted net loss per share:
 
                     
   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
    2026     2025     2026     2025  
                     
Net loss attributable to common stockholders, basic and diluted
 $(4,564,815)    (4,194,821)    (8,187,810)    (14,677,582) 
Weighted-average common shares and pre-funded warrants outstanding, basic and diluted
  8,660,381    2,050,761    5,136,109    1,586,992 
Basic and diluted loss per share
 $(0.53)    (2.05)    (1.59)    (9.25) 
 
The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding because they would be anti-dilutive:
 
                     
   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
    2026     2025     2026     2025  
Options to purchase common stock
  193,068    229,112    193,068    229,112 
Restricted stock units
  70,355     —    70,355     — 
Warrants to purchase common stock, in connection with April 2023 financing
  3,442    3,442    3,442    3,442 
November 2023 convertible notes, if converted   —    286,655    —    286,655 
Warrants to purchase common stock, in connection with November 2023 financing
  290,256    290,256    290,256    290,256 
Warrants to purchase common stock, in connection with June 2025 financing
  5,287    5,287    5,287    5,287 
Warrants to purchase common stock, in connection with August 2025 financing
  670,463    1,131,422    670,463    1,131,422 
November 2025 convertible notes and PIK interest, if converted
  874,234     —    874,234     — 
Warrants to purchase common stock, in connection with November 2025 financing
  3,275,748     —    3,275,748     — 
Warrants to purchase common stock, in connection with August 2026 financing
  18,749,998     —    18,749,998     — 
Warrants to purchase common stock
  7,083    7,083    7,083    7,083 
Total potential shares
  24,139,934    1,953,257    24,139,934    1,953,257 
 
(14)
Income Taxes
 
The effective tax rate of approximately 0% for the nine months ended September 30, 2026 and 2025 was lower than the statutory rate due to the Company remaining in a full valuation allowance position.
 
25

Table of Contents
(15)
Segment Reporting
 
In accordance with FASB ASC Topic 280, Segment Reporting, the Company has determined that it operates as a single business segment, which is the development and commercialization of therapeutic and diagnostic products that service women’s reproductive health needs (fertility and permanent birth control).
 
The determination of a single business segment is consistent with the financial information regularly provided to the Company’s chief operating decision maker (“CODM”). As a single reportable segment entity, the Company’s segment performance measure is net loss attributable to stockholders. The measurement of segment assets is reported on the balance sheet as total assets. The Company’s CODM consists of its Chief Executive Officer and Chief Financial Officer, who together review and evaluate net income (loss) for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods.
 
Significant segment expenses, as provided to the CODM, are as follows:
 
                     
   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
    2026     2025     2026     2025  
Sales
 $404,597    729,394    1,161,313    1,479,926 
Cost of sales (excluding depreciation expense)
  187,496    293,838    488,538    569,275 
                     
Research and development expense
  549,780    269,036    1,604,594    1,317,416 
Other research and development expense 1
  1,393,147    1,112,986    3,594,612    4,447,507 
Total research and development expense
  1,942,927    1,382,022    5,199,206    5,764,923 
                     
Sales and marketing expense
  943,002    1,143,805    3,552,755    3,037,349 
General and administrative expense
  1,704,091    1,477,800    5,418,059    4,817,485 
Depreciation and amortization expense
  77,091    85,697    242,172    256,835 
Total operating expenses
  4,667,111    4,089,324    14,412,192    13,876,592 
                     
Total other income (expense), net
  (114,805)    (541,053)    5,552,472    (1,715,829) 
Loss before income taxes
  (4,564,815)    (4,194,821)    (8,186,945)    (14,681,770) 
Income tax expense (benefit)
   —     —    865    (4,188) 
Net loss
 $(4,564,815)    (4,194,821)    (8,187,810)    (14,677,582) 
 
1 Other research and development expense includes clinical affairs, regulatory, manufacturing and quality assurance expenses.
 
(16)
Other income (expense), net
 
The Company incurred the following other income (expense), net for the three and nine months ended September 30, 2026 and 2025:
 
                     
   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
    2026     2025     2026     2025  
Interest income
 $85,610    17,315    155,131    53,488 
PIK interest and amortization of debt issuance costs and discount for 2023 and 2025 Notes
  (196,427)    (426,541)    (559,084)    (1,173,153) 
Interest expense
  (3,988)    (105,532)    (3,988)    (309,869) 
Change in fair value of Conversion Option liability
   —     —    1,732,413     — 
Change in fair value of Warrants liabilities
   —     —    4,228,000     — 
Issuance costs for AMPA
   —    (26,295)     —    (286,295) 
Total other income (expense), net
 $(114,805)    (541,053)    5,552,472    (1,715,829) 
 
26

Table of Contents
(17)
Subsequent Events
 
On October 30, 2026, Kenneth D. Eichenbaum, M.D., M.S.E., informed the board of directors (the “Board”) of the Company of his resignation as a director of the Company, effective as of that date. On October 30, 2026, the Board appointed John Moorhead as a director of the Company, effective as of that date.  
 
27

Table of Contents
Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
 
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission, or the SEC, on March 31, 2026. This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “goal,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “predict,” “potential” and similar expressions intended to identify forward-looking statements and reflect our beliefs and opinions on the relevant subject. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Quarterly Report on Form 10-Q. The forward-looking statements included in this Quarterly Report on Form 10-Q are made only as of the date hereof. These statements are based upon information available to us as of the filing date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.
 
Overview
 
We are a leading biomedical innovator, addressing significant unmet needs in women’s health worldwide, with a broad patent-protected portfolio of disruptive, accessible, in-office therapeutic and diagnostic products. The Company is a U.S. manufacturer that has received global regulatory approvals for its product portfolio, which is currently being commercialized in the U.S. and key international markets. FemaSeed® Intratubal Insemination, a groundbreaking first-step infertility treatment delivering sperm directly to the site of conception, is U.S. FDA-cleared and approved in Europe, United Kingdom (“UK”), Canada, Israel, Australia and New Zealand. A peer-reviewed publication of positive data from its pivotal clinical trial of FemaSeed demonstrated effectiveness and safety with high satisfaction from both patients and practitioners. FemSperm® includes collection and preparation and SpermVue™ includes at-home and in-office analysis kits, designed to expand our infertility portfolio and, for the first time, enable gynecologists to perform in-office sperm preparation and analysis for use with FemaSeed. FemVue®, a companion diagnostic for fallopian tube assessment via ultrasound, is U.S. FDA-cleared and approved in Europe, UK, Canada, Japan, Israel, Australia and New Zealand. FemHSG™ Catheter, used with FemVue for in-office ultrasound-based evaluation, is CE mark approved in Europe. FemVue Controlled is a U.S. FDA-cleared diagnostic device and is the next-generation design integrating features of FemVue and FemChec® technologies into a single platform, enabling multiple clinical uses within one solution, including confirmation of tubal patency prior to use with FemaSeed. FemCerv®, an endocervical tissue sampler for cervical cancer diagnosis, is U.S. FDA-cleared and approved in Europe, UK, Canada, Israel and New Zealand.
 
28

Table of Contents
FemBloc® permanent birth control is a revolutionary first-in-class non-surgical solution which involves minimally-invasive placement of a patented delivery system for precise delivery of our proprietary synthetic tissue adhesive (blended polymer) into both fallopian tubes simultaneously. Over time, the blended polymer fully degrades and produces nonfunctional scar tissue to permanently block the fallopian tubes in a safe and natural approach. This is in stark contrast to centuries-old surgical sterilization with reported risks that include infection, minor or major bleeding, injury to nearby organs, anesthesia-related events, and even death. Along with the various surgical risks, some patients may not qualify as good surgical candidates due to obesity or medical comorbidities. The FemBloc non-surgical approach has the potential to offer a safe and effective, more accessible in-office alternative with fewer risks, contraindications, and substantially lower cost than the surgical alternative. A peer-reviewed publication of positive data from its initial clinical trials of FemBloc has demonstrated compelling effectiveness and five-year safety with high satisfaction from both patients and practitioners. In March 2025, we announced Conformité Européenne (“CE”) mark certification under European Union (“EU”) Medical Device Regulation (“MDR”) as the first regulatory approval in the world for the FemBloc delivery system for non-surgical female permanent birth control and in June 2025, we announced CE mark certification under EU MDR for the class III blended polymer component, achieving approval for the entire FemBloc system in the EU. In August and September 2025, we announced UK and New Zealand regulatory approvals, respectively, for FemBloc. In March and September 2025, we announced strategic distribution partnerships for FemBloc in Spain and the France/Benelux region, respectively. We received FDA approval in November 2025 of our investigational device exemption (“IDE”) supplement to move forward to the final phase of the pivotal clinical trial (clinicaltrials.gov: NCT05977751) for U.S. approval. In March 2026, we announced the initiation of enrollment in this final phase. FemChec, a companion diagnostic product for FemBloc’s ultrasound-based confirmation test, is U.S. FDA-cleared and approved in Europe, UK, Canada, Israel, Australia and New Zealand.
 
We are a woman-founded and led company with an expansive, internally created intellectual property portfolio with approximately 244 issued patents globally, in-house chemistry, manufacturing, and controls (CMC) and device manufacturing capabilities and proven ability to develop products with commercialization efforts underway. Our suite of products and U.S. product candidate address what we believe are multi-billion dollar global market segments in which there has been little advancement for many years, helping women avoid pharmaceutical solutions, implants and surgery that can be expensive and expose women to harm.
 
Corporate Update
 
On August 7, 2026, we announced a $30 million private placement with potential total proceeds of up to $85 million upon full cash exercise of warrants to advance commercialization of FemaSeed fertility portfolio and conduct FemBloc pivotal trial to support U.S. approval.
 
On August 12, 2026, we announced the issuance of patents in the U.S. and key international markets that expand intellectual property protection for the blended polymer component of FemBloc, the Company’s non-surgical permanent birth control technology.
 
On August 19, 2026, we announced the FDA approval of the modular premarket approval application (PMA) pathway for FemBloc.
 
On August 26, 2026, we announced a partnership with UNC Health to introduce our female and male fertility diagnostics, FemVue®  and SpermVue™, together with FemaSeed®  Complete, an in-office intratubal insemination solution designed as a first-line fertility treatment, within UNC Health OB/GYN practice locations.
 
On September 9, 2026, we announced a partnership with CapexMD to expand patient access to our FemaSeed®-led fertility portfolio through dedicated financing solutions. The partnership will support access to FemaSeed® Complete, an in-office intratubal insemination solution designed as a first-line fertility treatment, together with Femasys’ female and male fertility diagnostics, FemVue® and SpermVueTM, across OB/GYN practices and fertility centers.
 
On September 15, 2026, we announced Minnesota Women’s Care will implement FemVue® for fertility diagnostic evaluation and FemaSeed® Complete for in-office first-line fertility treatment across its four OB/GYN practice locations.
 
On October 8, 2026, we announced that we will exhibit at the American Society for Reproductive Medicine (ASRM) 2026 Scientific Congress & Expo October 24-28 in Baltimore, Maryland.
 
On October 14, 2026, we announced that the number of actively enrolling sites in our FemBloc® FINALE trial to support U.S. approval doubled to twelve sites.
 
On October 20, 2026, we announced a partnership with SandsRx Pharmacy to support our FemaSeed®  fertility portfolio launch to OB/GYNs.
 
On October 30, 2026, we announced the appointment of John Moorhead to our Board of Directors.
 
29

Table of Contents
Reverse Stock Split
 
On June 5, 2026, the Company filed an amendment to its Eleventh Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company’s common stock, par value $0.001 per share, at a ratio of 1-for-20 (the “Reverse Stock Split”). The Reverse Stock Split did not change the authorized number of shares of the Company’s common stock. The Amendment was authorized by the stockholders of the Company at the Company’s special meeting of stockholders held on April 29, 2026.
 
Pursuant to the Amendment, on June 5, 2026, every 20 shares of common stock were automatically converted into one share of common stock, without any change in par value per share. No fractional shares were issued, and any fractional shares resulting from the Reverse Stock Split were rounded up to the nearest whole share at the Depository Trust Company (DTC) participant level.
 
The Reverse Stock Split applied to the Company’s outstanding warrants, stock options and restricted stock units. The number of shares of common stock into which these outstanding securities are convertible or exercisable was adjusted proportionately as a result of the Reverse Stock Split. The exercise prices of outstanding warrants and stock options were also proportionately adjusted in accordance with the terms of those securities and the Company’s equity incentive plans. The number of shares of common stock reserved for future issuance under the Company’s 2021 Equity Incentive Plan was also proportionately adjusted.
 
The Reverse Stock Split became effective at 8:40 a.m. Eastern Time on June 5, 2026, and the Company’s common stock began trading on a split-adjusted basis at the opening of trading on June 8, 2026. All shares of common stock, including common stock underlying warrants, stock options and restricted stock units, as well as all conversion ratios, exercise prices, conversion prices and per share information in the condensed financial statements have been retroactively adjusted to reflect the 1-for-20 Reverse Stock Split for all periods presented.
 
Results of Operations
 
Comparison of the Three Months Ended September 30, 2026 and 2025
 
The following table shows our results of operations for the three months ended September 30, 2026 and 2025:
 
                       
   Three Months Ended
September 30,
         
    2026   2025     Change     %
Change
 
Sales
 $404,597    729,394    (324,797)    (44.5)%
Cost of sales (excluding depreciation expense)
  187,496    293,838    (106,342)    (36.2)%
                       
Operating expenses:
                     
Research and development
  1,942,927    1,382,022    560,905    40.6%
Sales and marketing
  943,002    1,143,805    (200,803)    (17.6)%
General and administrative
  1,704,091    1,477,800    226,291    15.3%
Depreciation and amortization
  77,091    85,697    (8,606)    (10.0)%
Total operating expenses
  4,667,111    4,089,324    577,787    14.1%
Loss from operations
  (4,450,010)    (3,653,768)    (796,242)    21.8%
Other income (expense):
                     
Interest income
  85,610    17,315    68,295    394.4%
Interest expense
  (200,415)    (532,073)    331,658    (62.3)%
Other expense
   —    (26,295)    26,295    (100.0)%
Total other expense, net
  (114,805)    (541,053)    426,248    (78.8)%
Loss before income taxes
  (4,564,815)    (4,194,821)    (369,994)    8.8%
Income tax expense
   —     —     —    0.0%
Net loss
 $(4,564,815)    (4,194,821)    (369,994)    8.8%
 
30

Table of Contents
Sales
 
Sales in the U.S. increased slightly to $347,039 in 2026 from $336,594 in 2025, while overall sales decreased by $324,797, or 44.5%, to $404,597 in 2026 from $729,394 in 2025. The overall decline was anticipated and reflects the timing of international FemBloc orders, consistent with distributors’ customary bulk-ordering practices. Distributors are utilizing existing inventory to support FemBloc post-market studies, with reorders expected after those studies are completed.
 
Cost of sales
 
Cost of sales decreased by $106,342, or 36.2%, to $187,496 for the three months ended September 30, 2026 from $293,838 for the three months ended September 30, 2025, and is attributed to decreased international sales.
 
Research and development
 
The following table summarizes our R&D expenses incurred during the periods presented:
 
           
   Three Months Ended
September 30,
 
    2026     2025  
Compensation and related personnel costs
 $1,178,730    1,037,538 
Clinical-related costs
  470,415    242,549 
Material and development costs
  185,104    7,448 
Professional and outside consultant costs
  91,049    76,793 
Regulatory and other costs
  17,629    17,694 
Total research and development expenses
 $1,942,927    1,382,022 
 
31

Table of Contents
R&D expenses increased by $560,905, or 40.6%, to $1,942,927 for the three months ended September 30, 2026 from $1,382,022 for the three months ended September 30, 2025. The increase primarily reflects the transition of development products into inventory to support commercialization during 2025, and increased clinical costs and compensation costs during 2026.
 
Sales and marketing
 
Sales and marketing expenses decreased by $200,803, or 17.6%, to $943,002 for the three months ended September 30, 2026 from $1,143,805 for the three months ended September 30, 2025. The decrease relates primarily to lower compensation costs.
 
General and administrative
 
General and administrative expenses increased by $226,291, or 15.3%, to $1,704,091 for the three months ended September 30, 2026 from $1,477,800 for the three months ended September 30, 2025. The increase resulted primarily from increased facility costs and professional fees.
 
Depreciation and amortization
 
Depreciation and amortization expenses decreased by $8,606, or 10.0%, to $77,091 for the three months ended September 30, 2026 from $85,697 for the three months ended September 30, 2025. The decrease resulted from certain fixed assets reaching the end of their useful lives and no longer depreciating.
 
Other expense, net
 
Other expense, net decreased by $426,248, or 78.8%, to $114,805 for the three months ended September 30, 2026 from $541,053 for the three months ended September 30, 2025. The decrease resulted from interest income earned on our cash and cash equivalents and reduced non-cash interest expense related to amortization for our convertible notes and AMPA issuance costs incurred in 2025. Refer to the table below for further details.
 
           
   Three Months Ended 
September 30,
 
    2026     2025  
Interest income
 $85,610    17,315 
PIK interest and amortization of debt issuance costs and discount for 2025 Notes
  (196,427)     — 
Amortization of debt issuance costs and discount for 2023 Notes
   —    (426,541) 
Interest expense
  (3,988)    (105,532) 
Issuance costs for AMPA
   —    (26,295) 
Total other expense, net
 $(114,805)    (541,053) 
 
Income tax expense
 
No income tax expense was incurred for the three months ended September 30, 2026 and 2025.
 
32

Table of Contents
Results of Operations
 
Comparison of the Nine Months Ended September 30, 2026 and 2025
 
The following table shows our results of operations for the nine months ended September 30, 2026 and 2025:
 
                       
   Nine Months Ended
September 30,
             
    2026     2025     Change     %
Change
 
Sales
 $1,161,313    1,479,926    (318,613)    (21.5)%
Cost of sales (excluding depreciation expense)
  488,538    569,275    (80,737)    (14.2)%
                       
Operating expenses:
                     
Research and development
  5,199,206    5,764,923    (565,717)    (9.8)%
Sales and marketing
  3,552,755    3,037,349    515,406    17.0%
General and administrative
  5,418,059    4,817,485    600,574    12.5%
Depreciation and amortization
  242,172    256,835    (14,663)    (5.7)%
Total operating expenses
  14,412,192    13,876,592    535,600    3.9%
Loss from operations
  (13,739,417)    (12,965,941)    (773,476)    6.0%
Other income (expense):
                     
Interest income
  155,131    53,488    101,643    190.0%
Change in fair value of Conversion Option liability
  1,732,413     —    1,732,413    100.0%
Change in fair value of Warrants liabilities
  4,228,000     —    4,228,000    100.0%
Interest expense
  (563,072)    (1,483,022)    919,950    (62.0)%
Other expense
   —    (286,295)    286,295    (100.0)%
Total other income (expense), net
  5,552,472    (1,715,829)    7,268,301    (423.6)%
Loss before income taxes
  (8,186,945)    (14,681,770)    6,494,825    (44.2)%
Income tax expense (benefit)
  865    (4,188)    5,053    (120.7)%
Net loss
 $(8,187,810)    (14,677,582)    6,489,772    (44.2)%
 
Sales
 
Sales in the U.S. increased slightly to $1,038,997 in 2026 from $1,015,168 in 2025, while overall sales decreased by $318,613, or 21.5%, to $1,161,313 in 2026 from $1,479,926 in 2025. The overall decline was anticipated and reflects the timing of international FemBloc orders, consistent with distributors’ customary bulk-ordering practices. Distributors are utilizing existing inventory to support FemBloc post-market studies, with reorders expected after those studies are completed.
 
Cost of sales
 
Cost of sales decreased by $80,737, or 14.2%, to $488,538 for the nine months ended September 30, 2026 from $569,275 for the nine months ended September 30, 2025, and is attributed to reduced international sales.
 
Research and development
 
The following table summarizes our R&D expenses incurred during the periods presented:
 
           
   Nine Months Ended
September 30,
 
    2026     2025  
Compensation and related personnel costs
 $3,154,710    3,592,293 
Clinical-related costs
  1,189,575    898,914 
Material and development costs
  477,799    332,813 
Professional and outside consultant costs
  301,082    380,736 
Regulatory and other costs
  76,040    560,167 
Total research and development expenses
 $5,199,206    5,764,923 
 
33

Table of Contents
R&D expenses decreased by $565,717, or 9.8%, to $5,199,206 for the nine months ended September 30, 2026 from $5,764,923 for the nine months ended September 30, 2025. The decrease primarily reflects lower compensation costs, regulatory fees and professional and outside consultant costs, partially offset by increased clinical costs and material and development costs.
 
Sales and marketing
 
Sales and marketing expenses increased by $515,406, or 17.0%, to $3,552,755 for the nine months ended September 30, 2026 from $3,037,349 for the nine months ended September 30, 2025. The increase resulted primarily from higher compensation costs, travel expenses and professional fees.
 
General and administrative
 
General and administrative expenses increased by $600,574, or 12.5%, to $5,418,059 for the nine months ended September 30, 2026 from $4,817,485 for the nine months ended September 30, 2025. The increase resulted primarily from increased professional fees and facility costs.
 
Depreciation and amortization
 
Depreciation and amortization expenses decreased by $14,663, or 5.7%, to $242,172 for the nine months ended September 30, 2026 from $256,835 for the nine months ended September 30, 2025. The decrease resulted from certain fixed assets reaching the end of their useful lives and no longer depreciating.
 
Other income (expense), net
 
Other income (expense), net increased by $7,268,301, or 423.6%, to $5,552,472 of income for the nine months ended September 30, 2026 from $1,715,829 of expense for the nine months ended September 30, 2025. The increase resulted from the change in fair value on the Conversion Option liability and Warrants liabilities, interest income earned on our cash and cash equivalents and reduced non-cash interest expense related to amortization for our convertible notes and AMPA issuance costs incurred in 2025. Refer to the table below for further details.
 
           
   Nine Months Ended 
September 30,
 
    2026     2025  
Interest income
 $155,131    53,488 
PIK interest and amortization of debt issuance costs and discount for 2025 Notes
  (559,084)     — 
Amortization of debt issuance costs and discount for 2023 Notes
   —    (1,173,153) 
Interest expense
  (3,988)    (309,869) 
Change in fair value of Conversion Option liability
  1,732,413     — 
Change in fair value of Warrants liabilities
  4,228,000     — 
Issuance costs for AMPA
   —    (286,295) 
Total other income (expense), net
 $5,552,472    (1,715,829) 
 
Income tax (expense) benefit
 
Income tax (expense) benefit increased by $5,053, or 120.7%, to $865 in expense for the nine months ended September 30, 2026 from a $4,188 benefit for the nine months ended September 30, 2025 due to an increase in non-deductible expenses in 2026.
 
34

Table of Contents
Liquidity and Capital Resources
 
Sources of liquidity
 
From our inception through September 30, 2026, our operations have been financed primarily by net proceeds from the sale of our common stock and convertible preferred stock, indebtedness and, to a lesser extent, product revenue. As of September 30, 2026, we had $23,913,946 of cash and cash equivalents and an accumulated deficit of $154,013,954.
 
On July 1, 2022, we filed a shelf registration statement to sell up to $150 million in common and preferred stock, debt securities and warrants (the “2022 Shelf”). Additionally, we entered into an Equity Distribution Agreement with Piper Sandler & Co. (the “Sales Agent”) and filed a related prospectus establishing an “at-the-market” facility, pursuant to which we may offer and sell shares of our common stock from time to time through the Sales Agent. Our 2022 Shelf remained in effect until a replacement shelf registration statement was declared effective on December 9, 2025, at which time the 2022 Shelf expired. In December 2025, we filed a new prospectus under the replacement shelf registration statement pursuant to which we may sell up to $9.8 million under the Equity Distribution Agreement. For the nine months ended September 30, 2026, we sold 31,195 shares of common stock for aggregate proceeds of approximately $353,000 under the Equity Distribution Agreement pursuant to the prospectus. As of September 30, 2026, approximately $9.4 million remained available under the prospectus, although the amount we were authorized to sell was subject to baby-shelf limitations. 
 
 
35

Table of Contents
In June 2025, we sold 180,000 shares of common stock in an underwritten public offering at $17.00 per share. Separately and concurrently, we sold 84,314 shares of common stock in a private placement at a price of $17.00 per share to certain existing institutional stockholders and at the price of $20.40 per share to certain directors and officers. Net proceeds from the transaction were $3,705,061.
 
On June 30, 2025, we entered into an Any Market Purchase Agreement (“Purchase Agreement” or “AMPA”) with Alumni Capital LP (“Alumni”) whereby we have the right, but not the obligation, to sell to Alumni up to an aggregate of $10 million in shares of common stock in a series of purchases until December 31, 2026. We may elect that Alumni purchase up to $1 million in shares of common stock (or up to $5 million if mutually agreed) at either (i) the lowest traded price for the four previous business days, multiplied by 90%, or (ii) up to the lesser of (a) $1 million in shares of common stock, or (b) 100% of the average daily trading volume of common stock for the previous two business days at the lowest daily dollar volume-weighted average price, multiplied by 97%. We are limited to issuances to Alumni of up to 19.99% of the shares of common stock outstanding immediately prior to the execution of the Purchase Agreement.
 
In August 2025, we sold an aggregate of (i) 521,730 shares of common stock in a public offering and to certain Company officers, (ii) pre-funded warrants to purchase up to 587,500 shares of common stock and (iii) common warrants to purchase up to 1,109,237 shares of common stock. Additionally, common warrants to purchase 22,185 shares of common stock were issued to the underwriter as compensation for services performed. The purchase price per share for the common stock was $7.20, except for shares sold to certain Company officers, which were priced at $10.31 per share. The purchase price per share for the pre-funded warrants was $7.20. The net proceeds from the August 2025 Financing at closing were approximately $7.1 million. As of September 30, 2026, 587,500 pre-funded warrants and 460,959 common warrants were exercised for approximately $3.3 million.
 
In November 2025, we entered into a definitive agreement for the issuance of (i) senior secured convertible notes in an aggregate principal amount of $12,000,000, convertible into 818,544 shares of common stock at a conversion price of $14.66 per share, (ii) Series A-1 Warrants to purchase up to an aggregate of 818,937 shares of common stock at an exercise price of $16.20 per share, subject to adjustments, (iii) Series B-1 Warrants to purchase an aggregate of 818,937 shares of common stock at an exercise price of $18.40 per share, subject to adjustments, and (iv) Series C-1 Warrants to purchase an aggregate of 818,937 shares of common stock at an exercise price of $22.00 per share, subject to adjustments. In March 2026, we modified the November 2025 agreement to remove the non-standard adjustments to the conversion price of the notes and exercise prices of the Series A-1 Warrants, Series B-1 Warrants and Series C-1 Warrants, upon a Share Combination Event. As consideration for this modification, we issued to the holders of the 2025 Notes and related Warrants new Series D-1 Warrants which allow the holders to purchase an aggregate number of 818,937 shares of the Company’s common stock at an exercise price of $11.60 per share. The financing resulted in aggregate gross proceeds of $12.0 million, with total potential funding of approximately $68 million, including the Series D-1 Warrants. In April 2026, shareholders approved the issuance of shares of common stock upon conversion of the 2025 Notes and exercise of the Series A-1, B-1, C-1, and D-1 Warrants, including any issuances to directors and officers of the Company who are holders of these instruments, in excess of 19.99% of the Company’s issued and outstanding shares of common stock (to the extent that anti-dilution or price adjustment provisions in the instruments result in an effective conversion or exercise price below the Nasdaq Minimum Price).
 
In August 2026, we completed a private placement resulting in net proceeds of approximately $27.4 million. Pursuant to the agreement, we issued 5,013,559 shares of common stock and pre-funded warrants to purchase up to 4,361,440 shares of common stock, together with accompanying warrants to purchase an aggregate of 18,749,998 shares of common stock. Each share of common stock or, in lieu thereof, each pre-funded warrant was sold together with one common and one milestone warrant. The combined purchase price was $3.20 per share of common stock and its accompanying warrants and $3.1999 for each pre-funded warrant and its accompanying warrants. The accompanying warrants have an exercise price of $2.95 per share and consist of common warrants to purchase up to 9,374,999 shares of common stock and milestone warrants to purchase up to 9,374,999 shares of common stock, which become exercisable on August 10, 2027 and contain specified revenue, market-price and registration conditions that may shorten their exercise period (see Note 10). If all accompanying warrants are exercised for cash, then we could receive up to an additional $55.3 million in gross proceeds. As of September 30, 2026, 281,250 pre-funded warrants were exercised for $16.
 
36

Table of Contents
Funding requirements
 
Based on our current operating plan, we believe that our current cash and cash equivalents as of September 30, 2026, together with anticipated revenues from product sales, will be sufficient to fund our operations, including the FemBloc clinical trial, for at least twelve months from the date these financial statements are issued. In addition, we could receive potential additional proceeds of up to $55.3 million upon full cash exercise of the milestone warrants and common warrants from our August 2026 Financing (see Note 10). However, our available capital may not be sufficient to advance our U.S. product candidate, FemBloc, through regulatory approval. Our estimate as to how long we expect our existing cash and cash equivalents to be able to continue to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate.
 
If we do not receive proceeds from the exercise of the milestone warrants and common warrants from the August 2026 Financing, we will need to raise additional capital to complete the U.S. development and EU commercialization of our product candidate, FemBloc, and the U.S. commercialization of our fertility portfolio, including FemaSeed. However, we can give no assurances that we will be able to secure additional sources of funds to support our commercialization efforts or operations, or, if such funds are available to us, that such additional financing will be sufficient to meet our needs or be on terms acceptable to us. In addition, our convertible notes contain restrictions that limit our ability to issue securities without complying with certain participation rights. This risk may increase if economic and market conditions deteriorate. If we are unable to obtain additional financing when needed, we may need to terminate, significantly modify, or delay the development of our U.S. product candidate, or we may need to obtain funds through collaborations or otherwise on terms that may require us to relinquish rights to our technologies or our U.S. product candidate that we might otherwise seek to develop or commercialize independently. If we are unable to raise adequate additional capital as and when required in the future, we could be forced to cease development and commercialization activities and terminate our operations, and you could experience a complete loss of your investment.
 
37

Table of Contents
We expect to continue to make substantial investments in our ongoing commercialization of our products and the pivotal trial that is designed to provide clinical evidence of the safety and effectiveness of our U.S. product candidate, FemBloc. We also expect to continue to make investments in research and development to develop future products, manufacturing, regulatory affairs and post-market clinical trials. We will additionally need to make investments in our sales and marketing organization for FemaSeed and FemBloc. Because of these and other factors, we expect to continue to incur substantial net losses and negative cash flows from operations for the foreseeable future.
 
Our future capital requirements will depend on many factors, including:
 
•
the cost, timing and results of our clinical trial and U.S. regulatory reviews;
 
•
the cost and timing of establishing sales, marketing, and distribution capabilities;
 
•
the timing, receipt, and amount of sales from our current and potential products;
 
•
our ability to continue manufacturing our products and U.S. product candidate and to secure the components, services, and supplies needed in their production;
 
•
the degree of success we experience in commercializing our products;
 
•
the emergence of competing or complementary technologies;
 
•
the cost of preparing, filing, prosecuting, maintaining, defending, and enforcing any patent claims and other intellectual property rights; and
 
•
the extent to which we acquire or invest in businesses, products, or technologies, although we currently have no commitments or agreements relating to any of these types of transactions.
 
38

Table of Contents
Cash Flows
 
Comparison of the Nine Months Ended September 30, 2026 and 2025
 
The following table summarizes our cash flows for the nine months ended September 30, 2026 and 2025:
 
           
 
   Nine Months Ended
September 30,
 
    2026     2025  
Net cash used in operating activities
 $(12,896,701)    (14,505,325) 
Net cash used in investing activities
  (122,332)    (433,383) 
Net cash provided by financing activities
  27,666,626    16,055,985 
Net change in cash and cash equivalents
 $14,647,593    1,117,277 
 
Operating activities
 
For the nine months ended September 30, 2026, cash used in operating activities was $12,896,701, attributable to a net loss of $8,187,810, net non-cash gains of $4,262,188 and a net change in our net operating assets and liabilities of $446,703. Non-cash activity primarily consisted of a change in fair value of the Conversion Option liability and Warrants liabilities of $1,732,413 and $4,228,000, respectively, $559,084 of PIK interest and amortization of the discount on convertible notes, $552,644 in share-based compensation, $344,325 in right-of-use asset amortization and $242,172 in depreciation and amortization. The change in our net operating assets and liabilities was primarily due to an increase in inventory of $426,122 and decreases in lease liabilities of $369,838 and accrued expenses of $362,555, partially offset by an increase in accounts payable of $58,330, decreases in accounts receivable of $382,822 and prepaid and other assets of $288,245. We intend to meet future operating cash requirements through increased sales of commercial products and fundraising, as discussed in Funding requirements.
 
For the nine months ended September 30, 2025, cash used in operating activities was $14,505,325, attributable to a net loss of $14,677,582 and a net change in our net operating assets and liabilities of $2,420,824, partially offset by non-cash charges of $2,593,081. Non-cash charges primarily consisted of $1,173,153 in amortization of the discount on convertible notes, $723,722 in share-based compensation, $386,198 in right-of-use asset amortization, $256,835 in depreciation and amortization and $53,173 in loss on property and equipment dispositions. The change in our net operating assets and liabilities was primarily due to increases in inventory of $2,737,651 and accounts receivable of $83,826, decreases in lease liabilities of $392,850, accrued expenses of $122,588 and other liabilities of $23,694, partially offset by an increase in accounts payable of $656,403 and decreases in prepaid and other assets of $283,382. We intend to meet future operating cash requirements through increased sales of commercial products and fundraising, as discussed in Funding requirements.
 
Investing activities
 
For the nine months ended September 30, 2026, cash used in investing activities for the purchase of property and equipment and acquisition of patents was $122,332.
 
For the nine months ended September 30, 2025, cash used in investing activities for the purchase of property and equipment and acquisition of patents was $433,383.
 
Financing activities
 
For the nine months ended September 30, 2026, cash provided by financing activities was $27,666,626, attributable to $27,371,798 in proceeds from the August 2026 financing, net of issuance costs, $342,334 in proceeds from sales under the at-the-market facility, net of issuance costs, $15,329 in proceeds from the issuance of shares under the ESPP and $16 for the exercise of pre-funded warrants. The proceeds were partially offset by repayment of note payable for $62,851.
 
For the nine months ended September 30, 2025, cash provided by financing activities was $16,055,985, attributable to $5,331,887 in proceeds from sales under the at-the-market facility, net of issuance costs, proceeds of $3,705,061 from the June 2025 financing, net of issuance costs, proceeds of $7,069,123 from the August 2025 financing, net of issuance costs and inclusive of exercised warrants, and $40,875 in proceeds from the issuance of shares under the ESPP. The proceeds were partially offset by repayment of note payable for $90,961.
 
39

Table of Contents
Critical Accounting Estimates
 
Management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these financial statements requires us to make estimates and assumptions for the reported amounts of assets, liabilities, revenue, expenses and related disclosures. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material.
 
40

Table of Contents
While our significant accounting policies are more fully described in Note 2 to our financial statements appearing in the Annual Report on Form 10-K for the year ended December 31, 2025 as filed on March 31, 2026, we believe the following discussion addresses our most critical accounting estimates, which are those that are most important to our financial condition and results of operations and require our most difficult, subjective and complex judgments.
 
Revenue recognition
 
Our policy is to recognize revenue when a customer obtains control of the promised goods under ASC 606, Revenue from Contracts with Customers, which we adopted effective January 1, 2018. The amount of revenue recognized reflects the consideration to which we expect to be entitled in exchange for these goods, and we have elected to exclude amounts collected from customers for all sales (and other similar) taxes from the transaction price. We do not have multiple performance obligations in our customer orders, so revenue is recognized upon shipment of our goods based upon contractually stated pricing at standard payment terms typically ranging from 30 to 60 days. All revenue is recognized at a point in time.
 
The majority of products sold directly to U.S. customers are shipped via common carrier, and the customer pays for shipping and handling and assumes control at Free on Board (FOB) shipping point. Products shipped to our international distributors are in accordance with their respective agreements; however, the shipping terms are generally EX-Works, reflecting that control is assumed by the distributor at the shipping point. Returns are only accepted with prior authorization from us. Items to be returned must be in original unopened cartons and are subject to a 30% restocking fee. As of September 30, 2026, we have not had a history of significant returns.
 
Convertible Notes, Conversion Option liability and Warrants liabilities
 
The Company accounts for debt and equity instruments issued in financing transactions, including the senior secured convertible notes (“2025 Notes”) and related Warrants issued in its November 2025 financing transaction, which require significant management judgments and estimates. The financial instruments issued contain complex embedded features, including conversion options, exercise price adjustment provisions, redemption features, and other settlement terms that require evaluation under applicable accounting guidance to determine whether such features should be classified as equity or derivative liabilities.
 
Management concluded that certain embedded conversion features within the 2025 Notes and the related Warrants were not indexed to the Company’s common stock under ASC 815-40 and therefore did not qualify for equity classification, primarily due to shareholder approval requirements that limited settlement in shares and, prior to the March 2026 modification, certain market-based adjustment provisions. Accordingly, the Conversion Option embedded in the 2025 Notes and the Warrants were recognized as derivative liabilities and initially measured at fair value in accordance with ASC 820, with subsequent changes in fair value recognized in earnings each reporting period.
 
In March 2026, the Company modified the 2025 Notes and related Warrants to remove certain market-based adjustment provisions and issued additional Series D-1 Warrants in connection with the modification. The Company evaluated the modification under the applicable accounting guidance and recorded the new Series D-1 Warrants as derivative liabilities at fair value upon issuance.
 
In April 2026, shareholders approved the issuance of shares underlying the 2025 Notes and Series A-1, B-1, C-1, and D-1 Warrants in excess of the Nasdaq 19.99% limitation. Following the approval, the Company reassessed the Conversion Option and Warrants under ASC 815-40 and determined that they met the criteria for equity classification. As a result, the instruments were reclassified from derivative liabilities to equity and are no longer subject to recurring fair value measurement.
 
The valuation of the derivative liabilities required the use of significant estimates and assumptions, including the Company’s stock price, expected volatility, expected term, risk-free interest rates, probability and timing of potential future events, and assumptions related to conversion and exercise probability. Management also exercised significant judgment in evaluating whether the Conversion Option and Warrants met the liability or equity classification criteria under ASC 815-40, particularly in connection with the March 2026 modification and the April 2026 shareholder approval. Changes in these assumptions could have materially impacted the estimated fair value of the derivative liabilities and the related gains or losses recognized in the Company’s condensed statements of operations, and the classification of these instruments.
 
In addition, the Company records the 2025 Notes at amortized cost and accretes the associated debt discount and issuance costs to interest expense using the effective interest method over the expected term of the instruments. The effective interest rate of the 2025 Notes was impacted by the initial allocation of proceeds between the debt host and derivative liabilities, which required significant management judgment.
 
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
 
Not applicable.
 
41

Table of Contents
Item 4.
Controls and Procedures
 
Evaluation of Disclosure Controls and Procedures
 
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (2) accumulated and communicated to our management, including to our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Our management, with the participation of our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial and accounting officer), has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our management has concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of September 30, 2026.
 
Changes in Internal Control over Financial Reporting
 
There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
 
Inherent Limitations on Effectiveness of Controls
 
Our management, including our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial and accounting officer), does not expect that our disclosure controls and procedures or internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and implemented, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues within a company are detected. The inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple errors or mistakes. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and may not be detected.
 
42

Table of Contents
PART II OTHER INFORMATION
 
Item 1.
Legal Proceedings
 
On September 2, 2026, Iroquois Master Fund, Ltd. and Iroquois Capital Investment Group LLC filed a motion for summary judgment in lieu of complaint against us in the Supreme Court of the State of New York, County of New York (Index No. 655038/2026), pursuant to CPLR § 3213, seeking payment under Senior Secured Convertible Notes issued by us on November 7, 2025. The plaintiffs allege that our August 7, 2026 Securities Purchase Agreement (closed August 10), under which we sold shares of common stock, pre-funded warrants and warrants to accredited investors, constituted a “Fundamental Transaction” under the 2025 Notes, triggering an obligation to immediately repay amounts due, plus interest and a prepayment premium. Plaintiffs seek an aggregate of approximately $3.1 million, plus prejudgment interest at 9% per annum from August 10, 2026, and have requested that their claim for attorneys’ fees be referred to a Special Referee.
 
We dispute the allegations and believe they are without merit, and intend to defend the action vigorously. The Company filed its opposition on October 13, 2026, and the motion was fully briefed as of October 22, 2026. The Company has not recorded an accrual related to this matter as of September 30, 2026, because it has determined that a loss is not probable, and it is unable to estimate a range of reasonably possible loss, if any, at this time.
 
Item 1A.
Risk Factors
 
Other than as set forth below, as of the date of this report, there are no material changes to our risk factors as previously disclosed in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025, and our Quarterly Report on Form 10-Q for the three months ended March 31, 2026.
 
There are risks associated with our convertible notes and warrants that could adversely affect our business and financial condition.
 
In November 2025, we issued $12 million aggregate principal amount senior secured convertible notes, convertible into shares of common stock at a conversion price of $14.66 per share. The convertible notes accrue interest at a rate of 8.5% per annum, payable annually in kind (“PIK”) by increasing the principal balance outstanding. The 2025 Notes mature in November 2035, unless earlier converted or redeemed. There are no assurances that we will have sufficient funds available to satisfy the payment due under our convertible notes at maturity, or that the holders will elect to convert the convertible notes into shares of our common stock.
 
The convertible note purchase agreement provides for standard and customary events of default, such as our failing to make timely payments and failing to timely comply with the reporting requirements of the Exchange Act. The convertible notes also contain customary affirmative and negative covenants, including limitations on incurrence of indebtedness, acquisition and investment transactions, the existence of liens, the repayment of indebtedness, the payment of cash in respect of dividends, distributions or redemptions, and the transfer of assets. Our cash flow may not be sufficient to allow us to pay the principal and accrued interest at maturity in November 2035. Our ability to make these payments depends on a number of factors, including our operating performance, competitive developments and financial market conditions, all of which are significantly affected by financial, business, economic, and other factors, many of which we are not able to control. The level of our indebtedness under the convertible notes could have other important consequences, including the following:
 
●
We may need to use a substantial portion of our cash flow from operations to pay interest and principal on the convertible notes, which would reduce funds available to us for other purposes such as product development and operations;
●
If we do not have sufficient cash to pay the principal and accrued interest on the convertible notes at maturity, we may be unable to refinance such indebtedness on terms favorable to us or at all;
●
Conversion of the convertible notes could result in significant dilution of our common stock and cause the market price of our common stock to decline.
 
Our capital structure gives rise to a significant and compounding risk of dilution to existing stockholders. The outstanding principal amount of the 2025 Notes, together with PIK interest as of September 30, 2026, is convertible into approximately 874,234 shares of common stock. As noted above, the 2025 Notes accrue PIK interest at a rate of 8.5% per annum by increasing the principal balance outstanding annually. This means the outstanding principal balance on which conversion shares are calculated will increase by approximately $1,020,000 in the first year, with further compounding in each subsequent year through maturity in November 2035. Over the ten-year term of the 2025 Notes, the cumulative effect of PIK interest compounding could result in the 2025 Notes being convertible into a materially greater number of shares than the 874,234 currently contemplated.
 
43

Table of Contents
In connection with the November 2025 financing, we also issued four series of warrants to purchase an aggregate of 3,275,748 shares of our common stock at exercise prices ranging from $11.60 to $22.00 per share. These warrants are immediately exercisable and, in the case of the Series A-1 Warrants, expire ten years from the date of issuance.
 
Taken together, if the 2025 Notes were fully converted at the current conversion price and all four series of warrants issued in connection with the November 2025 financing were exercised in full, the aggregate number of shares issuable would be approximately 4,149,982, representing a substantial increase from the 8,656,277 shares of common stock outstanding as of September 30, 2026. This dilution could be further compounded by: (i) future issuances under our at-the-market offering facility; (ii) issuances under the Alumni Capital Any Market Purchase Agreement; and (iii) the exercise of the remaining 976,531 warrants outstanding from our prior financings.
 
In the August 2026 private placement, we issued 5,013,559 shares of common stock, pre-funded warrants to purchase 4,361,440 shares, and common and milestone warrants to purchase an additional 18,749,998 shares. The pre-funded warrants have an exercise price of $0.0001 per share, and the common and milestone warrants have an initial exercise price of $2.95 per share.
 
Subject to specified exceptions, the August 2026 common and milestone warrants provide weighted-average anti-dilution protection that reduces their exercise price and increases the shares issuable if we issue shares at a lower price. Exercise of the August 2026 warrants, including any additional shares resulting from these adjustments, could further dilute existing stockholders.
 
Any such dilution could cause the market price of our common stock to decline significantly. Investors should be aware that conversion of the 2025 Notes and exercise of the warrants, including those issued in the August 2026 private placement, are entirely at the election of the holders (or in the case of certain forced conversion and forced exercise provisions, at our election or automatically upon specified events), and that we cannot predict when or whether any such events will occur. We cannot assure you that the holders will not elect to convert or exercise their instruments at times that are disadvantageous to existing stockholders, including at times when we may be seeking to raise additional equity capital.
Litigation relating to our 2025 Notes could adversely affect our liquidity, financial condition and results of operations.
We are defendants in an action brought by Iroquois Master Fund, Ltd. and Iroquois Capital Investment Group LLC alleging that our August 2026 financing triggered an obligation to repay our 2025 Notes, including interest and a prepayment premium. The plaintiffs seek approximately $3.1 million, plus prejudgment interest and attorneys’ fees. Although we believe the allegations are without merit and intend to defend the action vigorously, we cannot predict its outcome. An adverse judgment or settlement could require substantial cash payments, reduce funds available for our operations and increase our need for additional financing, which may not be available on acceptable terms or at all. Regardless of the outcome, this litigation could result in significant legal expenses and divert management’s attention from our business, materially adversely affecting our liquidity, financial condition and results of operations.
 
44

Table of Contents
Item 2.
Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities
 
On August 10, 2026, we completed a private placement of 5,013,559 shares of common stock, pre-funded warrants to purchase up to 4,361,440 shares of common stock, and accompanying common and milestone warrants to purchase an aggregate of 18,749,998 shares of common stock, for aggregate gross proceeds of approximately $30.0 million and net proceeds of $27.4 million, after deducting issuance costs. We intend to use the net proceeds for general corporate purposes. The securities were issued to accredited investors in reliance on Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D thereunder, without general solicitation. For additional information, see Note 10 to the condensed financial statements included in this Quarterly Report.
 
Item 3.
Defaults Upon Senior Securities
 
None.
 
Item 4.
Mine Safety Disclosures
 
Not applicable.
 
Item 5.
Other Information
 
During the period covered by this Quarterly Report, none of our directors or executive officers have adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended).
 
45

Table of Contents
Item 6.
Exhibits
 
           
      Incorporated
by Reference
 
Exhibit
       
Number
Description of Document
Schedule/Form File
Number
Exhibit Filing
Date
           
3.1
Eleventh Amended and Restated Certificate of Incorporation of Femasys Inc.
Form 8-K 001-40492 3.1 June 22, 2021
           
3.2
Certificate of Amendment to the Eleventh Amended and Restated Certificate of Incorporation of Femasys Inc.
Form 8-K 001-40492 3.1 June 5, 2026
           
3.3
Amended and Restated Bylaws of Femasys Inc.
Form 8-K 001-40492 3.2 June 22, 2021
           
3.4
First Amendment to the Amended and Restated Bylaws of Femasys Inc.
Form 8-K 001-40492 3.1 March 30, 2023
           
4.1
Form of Pre-Funded Warrant
Form 8-K 001-40492 4.1 August 11, 2026
           
4.2
Form of Common Warrant
Form 8-K 001-40492 4.2 August 11, 2026
           
4.3
Form of Common Warrant (Milestone)
Form 8-K 001-40492 4.3 August 11, 2026
           
10.1
Securities Purchase Agreement, dated as of August 7, 2026, by and among Femasys Inc. and the Purchasers party thereto
Form 8-K 001-40492 10.1 August 11, 2026
           
10.2
Registration Rights Agreement, dated as of August 7, 2026, by and among Femasys Inc. and the Purchasers party thereto
Form 8-K 001-40492 10.2 August 11, 2026
           
10.3
Side Letter, dated as of August 7, 2026, by and between Femasys Inc. and Nantahala Capital Management, LLC
Form 8-K 001-40492 10.3 August 11, 2026
 
46

Table of Contents
  
31.1*
Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
   
31.2*
Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
   
32.1**
Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
   
32.2**
Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
   
101.INS*
Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
   
101.SCH*
Inline XBRL Taxonomy Extension Schema Document
   
101.CAL*
Inline XBRL Taxonomy Extension Calculation Linkbase Document
   
101.DEF*
Inline XBRL Taxonomy Extension Definition Linkbase Document
   
101.LAB*
Inline XBRL Taxonomy Extension Label Linkbase Document
   
101.PRE*
Inline XBRL Taxonomy Extension Presentation Linkbase Document
   
104*
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
 
*
Filed herewith
**   Furnished herewith
 
47

Table of Contents
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Suwanee, State of Georgia, on this 13th day of November 2026.
 
     
 
FEMASYS INC.
     
Dated: November 13, 2026
By: /s/ Kathy Lee-Sepsick
 
 
Kathy Lee-Sepsick
 
 
Chief Executive Officer and President
 
 
(principal executive officer)
 
     
Dated: November 13, 2026
By: /s/ Dov Elefant
 
 
Dov Elefant
 
 
Chief Financial Officer
 
 
(principal financial and accounting officer)
 
 
 

2026 0.05 2024-11-30 2035-11-30 P7Y6M P10Y P10Y 2024-11-30 1 1 1 0001339005 false Q3 --12-31 0001339005 2026-01-01 2026-09-30 0001339005 2026-11-12 0001339005 2026-09-30 0001339005 2025-12-31 0001339005 2026-07-01 2026-09-30 0001339005 2025-07-01 2025-09-30 0001339005 2025-01-01 2025-09-30 0001339005 us-gaap:CommonStockMember 2026-06-30 0001339005 us-gaap:TreasuryStockCommonMember 2026-06-30 0001339005 us-gaap:WarrantMember 2026-06-30 0001339005 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001339005 us-gaap:RetainedEarningsMember 2026-06-30 0001339005 2026-06-30 0001339005 femy:WarrantsElevenMember us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001339005 femy:WarrantsElevenMember us-gaap:TreasuryStockCommonMember 2026-07-01 2026-09-30 0001339005 femy:WarrantsElevenMember us-gaap:WarrantMember 2026-07-01 2026-09-30 0001339005 femy:WarrantsElevenMember us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001339005 femy:WarrantsElevenMember us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001339005 femy:WarrantsElevenMember 2026-07-01 2026-09-30 0001339005 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001339005 us-gaap:TreasuryStockCommonMember 2026-07-01 2026-09-30 0001339005 us-gaap:WarrantMember 2026-07-01 2026-09-30 0001339005 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001339005 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001339005 us-gaap:CommonStockMember 2026-09-30 0001339005 us-gaap:TreasuryStockCommonMember 2026-09-30 0001339005 us-gaap:WarrantMember 2026-09-30 0001339005 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001339005 us-gaap:RetainedEarningsMember 2026-09-30 0001339005 us-gaap:CommonStockMember 2025-12-31 0001339005 us-gaap:TreasuryStockCommonMember 2025-12-31 0001339005 us-gaap:WarrantMember 2025-12-31 0001339005 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001339005 us-gaap:RetainedEarningsMember 2025-12-31 0001339005 us-gaap:CommonStockMember 2026-01-01 2026-09-30 0001339005 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-09-30 0001339005 us-gaap:WarrantMember 2026-01-01 2026-09-30 0001339005 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-09-30 0001339005 us-gaap:RetainedEarningsMember 2026-01-01 2026-09-30 0001339005 femy:WarrantsElevenMember us-gaap:CommonStockMember 2026-01-01 2026-09-30 0001339005 femy:WarrantsElevenMember us-gaap:TreasuryStockCommonMember 2026-01-01 2026-09-30 0001339005 femy:WarrantsElevenMember us-gaap:WarrantMember 2026-01-01 2026-09-30 0001339005 femy:WarrantsElevenMember us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-09-30 0001339005 femy:WarrantsElevenMember us-gaap:RetainedEarningsMember 2026-01-01 2026-09-30 0001339005 femy:WarrantsElevenMember 2026-01-01 2026-09-30 0001339005 femy:WarrantsTenMember us-gaap:CommonStockMember 2026-01-01 2026-09-30 0001339005 femy:WarrantsTenMember us-gaap:TreasuryStockCommonMember 2026-01-01 2026-09-30 0001339005 femy:WarrantsTenMember us-gaap:WarrantMember 2026-01-01 2026-09-30 0001339005 femy:WarrantsTenMember us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-09-30 0001339005 femy:WarrantsTenMember us-gaap:RetainedEarningsMember 2026-01-01 2026-09-30 0001339005 femy:WarrantsTenMember 2026-01-01 2026-09-30 0001339005 us-gaap:CommonStockMember 2025-06-30 0001339005 us-gaap:TreasuryStockCommonMember 2025-06-30 0001339005 us-gaap:WarrantMember 2025-06-30 0001339005 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001339005 us-gaap:RetainedEarningsMember 2025-06-30 0001339005 2025-06-30 0001339005 femy:WarrantsNineMember us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001339005 femy:WarrantsNineMember us-gaap:TreasuryStockCommonMember 2025-07-01 2025-09-30 0001339005 femy:WarrantsNineMember us-gaap:WarrantMember 2025-07-01 2025-09-30 0001339005 femy:WarrantsNineMember us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001339005 femy:WarrantsNineMember us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001339005 femy:WarrantsNineMember 2025-07-01 2025-09-30 0001339005 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001339005 us-gaap:TreasuryStockCommonMember 2025-07-01 2025-09-30 0001339005 us-gaap:WarrantMember 2025-07-01 2025-09-30 0001339005 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001339005 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001339005 us-gaap:CommonStockMember 2025-09-30 0001339005 us-gaap:TreasuryStockCommonMember 2025-09-30 0001339005 us-gaap:WarrantMember 2025-09-30 0001339005 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001339005 us-gaap:RetainedEarningsMember 2025-09-30 0001339005 2025-09-30 0001339005 us-gaap:CommonStockMember 2024-12-31 0001339005 us-gaap:TreasuryStockCommonMember 2024-12-31 0001339005 us-gaap:WarrantMember 2024-12-31 0001339005 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001339005 us-gaap:RetainedEarningsMember 2024-12-31 0001339005 2024-12-31 0001339005 us-gaap:CommonStockMember 2025-01-01 2025-09-30 0001339005 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-09-30 0001339005 us-gaap:WarrantMember 2025-01-01 2025-09-30 0001339005 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-09-30 0001339005 us-gaap:RetainedEarningsMember 2025-01-01 2025-09-30 0001339005 femy:WarrantsEightMember us-gaap:CommonStockMember 2025-01-01 2025-09-30 0001339005 femy:WarrantsEightMember us-gaap:TreasuryStockCommonMember 2025-01-01 2025-09-30 0001339005 femy:WarrantsEightMember us-gaap:WarrantMember 2025-01-01 2025-09-30 0001339005 femy:WarrantsEightMember us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-09-30 0001339005 femy:WarrantsEightMember us-gaap:RetainedEarningsMember 2025-01-01 2025-09-30 0001339005 femy:WarrantsEightMember 2025-01-01 2025-09-30 0001339005 femy:WarrantsNineMember us-gaap:CommonStockMember 2025-01-01 2025-09-30 0001339005 femy:WarrantsNineMember us-gaap:TreasuryStockCommonMember 2025-01-01 2025-09-30 0001339005 femy:WarrantsNineMember us-gaap:WarrantMember 2025-01-01 2025-09-30 0001339005 femy:WarrantsNineMember us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-09-30 0001339005 femy:WarrantsNineMember us-gaap:RetainedEarningsMember 2025-01-01 2025-09-30 0001339005 femy:WarrantsNineMember 2025-01-01 2025-09-30 0001339005 femy:WarrantsEightMember 2026-01-01 2026-09-30 0001339005 femy:WarrantsNineMember 2026-01-01 2026-09-30 0001339005 femy:WarrantsElevenMember 2025-01-01 2025-09-30 0001339005 femy:November2025FinancingMember 2026-01-01 2026-09-30 0001339005 femy:November2025FinancingMember 2025-01-01 2025-09-30 0001339005 femy:November2023FinancingMember 2026-01-01 2026-09-30 0001339005 femy:November2023FinancingMember 2025-01-01 2025-09-30 0001339005 2026-06-05 0001339005 2026-06-05 2026-06-05 0001339005 femy:November2025FinancingMember us-gaap:ConvertibleDebtMember 2026-04-29 2026-04-29 0001339005 femy:November2025FinancingMember femy:EmbeddedConversionOptionMember us-gaap:MeasurementInputPriceVolatilityMember 2026-04-29 0001339005 femy:November2025FinancingMember us-gaap:FairValueInputsLevel3Member 2026-09-30 0001339005 femy:EmbeddedConversionOptionMember 2025-12-31 0001339005 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2025-12-31 0001339005 femy:EmbeddedConversionOptionMember 2026-01-01 2026-04-29 0001339005 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2026-01-01 2026-04-29 0001339005 femy:EmbeddedConversionOptionMember 2026-04-29 0001339005 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2026-04-29 0001339005 femy:November2025FinancingMember femy:EmbeddedConversionOptionMember 2026-04-29 0001339005 femy:November2025FinancingMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2026-04-29 0001339005 femy:November2025FinancingMember femy:EmbeddedConversionOptionMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-04-29 0001339005 femy:November2025FinancingMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-04-29 0001339005 femy:November2025FinancingMember femy:EmbeddedConversionOptionMember us-gaap:MeasurementInputExpectedDividendRateMember 2026-04-29 0001339005 femy:November2025FinancingMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:MeasurementInputExpectedDividendRateMember 2026-04-29 0001339005 femy:November2025FinancingMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:MeasurementInputPriceVolatilityMember 2026-04-29 0001339005 femy:November2025FinancingMember femy:EmbeddedConversionOptionMember us-gaap:MeasurementInputExercisePriceMember 2026-04-29 0001339005 srt:MinimumMember femy:November2025FinancingMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:MeasurementInputExercisePriceMember 2026-04-29 0001339005 srt:MaximumMember femy:November2025FinancingMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:MeasurementInputExercisePriceMember 2026-04-29 0001339005 femy:November2025FinancingMember femy:EmbeddedConversionOptionMember us-gaap:MeasurementInputSharePriceMember 2026-04-29 0001339005 femy:November2025FinancingMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:MeasurementInputSharePriceMember 2026-04-29 0001339005 srt:MinimumMember femy:November2025FinancingMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2026-04-29 0001339005 srt:MaximumMember femy:November2025FinancingMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2026-04-29 0001339005 femy:MoneyMarketFundsCertificatesOfDepositAndShorttermUSTreasuryBillsMember us-gaap:FairValueInputsLevel1Member 2026-09-30 0001339005 femy:MoneyMarketFundsCertificatesOfDepositAndShorttermUSTreasuryBillsMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0001339005 srt:MinimumMember 2026-01-01 2026-09-30 0001339005 srt:MaximumMember 2026-01-01 2026-09-30 0001339005 country:US 2026-07-01 2026-09-30 0001339005 country:US 2025-07-01 2025-09-30 0001339005 country:US 2026-01-01 2026-09-30 0001339005 country:US 2025-01-01 2025-09-30 0001339005 us-gaap:NonUsMember 2026-07-01 2026-09-30 0001339005 us-gaap:NonUsMember 2025-07-01 2025-09-30 0001339005 us-gaap:NonUsMember 2026-01-01 2026-09-30 0001339005 us-gaap:NonUsMember 2025-01-01 2025-09-30 0001339005 femy:PromissoryNotesMember femy:AFCOCreditCorporationMember 2025-07-01 2025-07-31 0001339005 femy:PromissoryNotesMember femy:AFCOCreditCorporationMember 2025-07-31 0001339005 femy:PromissoryNotesMember femy:AFCOCreditCorporationMember 2026-07-01 2026-07-31 0001339005 femy:PromissoryNotesMember femy:AFCOCreditCorporationMember 2026-07-31 0001339005 femy:PromissoryNotesMember femy:AFCOCreditCorporationMember 2026-09-30 0001339005 femy:PromissoryNotesMember femy:AFCOCreditCorporationMember 2025-12-31 0001339005 femy:PromissoryNotesMember femy:AFCOCreditCorporationMember 2026-07-01 2026-09-30 0001339005 femy:PromissoryNotesMember femy:AFCOCreditCorporationMember 2026-01-01 2026-09-30 0001339005 femy:PromissoryNotesMember femy:AFCOCreditCorporationMember 2025-07-01 2025-09-30 0001339005 femy:PromissoryNotesMember femy:AFCOCreditCorporationMember 2025-01-01 2025-09-30 0001339005 femy:November2023FinancingMember us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2023-11-21 0001339005 femy:November2023FinancingMember femy:SeriesAWarrantsMember 2023-11-21 0001339005 femy:November2023FinancingMember us-gaap:ConvertibleDebtMember femy:SeriesBWarrantsMember 2023-11-21 0001339005 femy:November2023FinancingMember 2023-11-21 2023-11-21 0001339005 femy:November2023FinancingMember us-gaap:ConvertibleDebtMember 2026-09-30 0001339005 femy:November2023FinancingMember 2025-11-01 2025-11-30 0001339005 femy:November2023FinancingMember 2026-04-01 2026-04-30 0001339005 femy:November2023FinancingMember us-gaap:ConvertibleDebtMember 2025-04-01 2025-04-30 0001339005 femy:November2023FinancingMember us-gaap:CommonStockMember 2025-04-01 2025-04-30 0001339005 femy:November2023FinancingMember us-gaap:ConvertibleDebtMember 2026-01-01 2026-09-30 0001339005 femy:November2023FinancingMember femy:SeriesAWarrantsMember 2026-09-30 0001339005 femy:November2023FinancingMember femy:SeriesAWarrantsMember 2023-11-21 2023-11-21 0001339005 femy:November2023FinancingMember femy:SeriesAWarrantsMember 2026-01-01 2026-09-30 0001339005 femy:November2023FinancingMember femy:SeriesBWarrantsMember 2026-09-30 0001339005 femy:November2023FinancingMember us-gaap:ConvertibleDebtMember 2025-07-01 2025-09-30 0001339005 femy:November2023FinancingMember femy:AFCOCreditCorporationMember us-gaap:ConvertibleDebtMember 2025-07-01 2025-09-30 0001339005 femy:November2023FinancingMember us-gaap:ConvertibleDebtMember 2025-01-01 2025-09-30 0001339005 femy:November2023FinancingMember femy:AFCOCreditCorporationMember us-gaap:ConvertibleDebtMember 2025-01-01 2025-09-30 0001339005 femy:November2025FinancingMember us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2025-11-30 0001339005 femy:November2025FinancingMember us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2025-11-01 2025-11-30 0001339005 femy:November2025FinancingMember femy:SeriesA1WarrantsMember 2025-11-30 0001339005 femy:November2025FinancingMember femy:SeriesB1WarrantsMember 2025-11-30 0001339005 femy:November2025FinancingMember femy:SeriesC1WarrantsMember 2025-11-30 0001339005 femy:November2025FinancingMember 2025-11-01 2025-11-30 0001339005 femy:November2025FinancingMember us-gaap:ConvertibleDebtMember 2026-09-30 0001339005 femy:November2025FinancingMember us-gaap:ConvertibleDebtMember 2026-01-01 2026-09-30 0001339005 femy:November2025FinancingMember us-gaap:ConvertibleDebtMember 2025-11-01 2025-11-30 0001339005 femy:November2025FinancingMember us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2026-09-30 0001339005 femy:November2025FinancingMember 2026-09-30 0001339005 femy:November2025FinancingMember femy:SeriesA1WarrantsMember 2026-09-30 0001339005 femy:November2025FinancingMember femy:SeriesB1WarrantsMember 2026-09-30 0001339005 femy:November2025FinancingMember femy:SeriesB1WarrantsMember 2026-01-01 2026-09-30 0001339005 femy:November2025FinancingMember femy:SeriesC1WarrantsMember 2026-09-30 0001339005 femy:November2025FinancingMember femy:SeriesC1WarrantsMember 2026-01-01 2026-09-30 0001339005 femy:November2025FinancingMember femy:SeriesD1WarrantsMember 2026-03-31 0001339005 femy:November2025FinancingMember 2026-07-01 2026-09-30 0001339005 femy:November2025FinancingMember femy:AFCOCreditCorporationMember 2026-07-01 2026-09-30 0001339005 femy:November2025FinancingMember femy:AFCOCreditCorporationMember 2026-01-01 2026-09-30 0001339005 femy:November2025FinancingMember us-gaap:ConvertibleDebtMember 2025-12-31 0001339005 femy:November2025FinancingMember us-gaap:PaymentInKindPIKNoteMember 2026-09-30 0001339005 femy:November2025FinancingMember us-gaap:PaymentInKindPIKNoteMember 2025-12-31 0001339005 srt:MaximumMember 2022-07-01 0001339005 srt:MaximumMember 2023-10-31 0001339005 srt:MaximumMember 2025-12-01 2025-12-31 0001339005 femy:UnderwrittenPublicOfferingMember 2025-06-01 2025-06-30 0001339005 femy:UnderwrittenPublicOfferingMember 2025-06-30 0001339005 us-gaap:PrivatePlacementMember 2025-06-01 2025-06-30 0001339005 us-gaap:PrivatePlacementMember 2025-06-30 0001339005 femy:DirectorsandOfficerMember us-gaap:PrivatePlacementMember 2025-06-30 0001339005 2025-06-01 2025-06-30 0001339005 femy:UnderwriterWarrantsMember 2025-06-30 0001339005 femy:UnderwriterWarrantsMember 2026-09-30 0001339005 femy:UnderwriterWarrantsMember 2025-06-01 2025-06-30 0001339005 srt:MaximumMember femy:PurchaseAgreementMember 2025-06-01 2025-06-30 0001339005 femy:PurchaseAgreementMember 2025-06-01 2025-06-30 0001339005 femy:PurchaseAgreementMember 2026-01-01 2026-09-30 0001339005 femy:PurchaseAgreementMember 2025-06-30 0001339005 femy:PurchaseAgreementMember 2026-09-30 0001339005 srt:MaximumMember femy:PurchaseAgreementMember 2026-01-01 2026-09-30 0001339005 femy:August2025FinancingMember 2025-08-25 2025-08-25 0001339005 femy:PreFundedWarrantsMember femy:August2025FinancingMember 2025-08-25 0001339005 femy:CommonWarrantsMember femy:August2025FinancingMember 2025-08-25 0001339005 femy:UnderwriterWarrantsMember femy:August2025FinancingMember 2025-08-25 0001339005 femy:CommonWarrantsMember femy:August2025FinancingMember 2026-09-30 0001339005 srt:OfficerMember femy:CommonWarrantsMember femy:August2025FinancingMember 2025-08-25 0001339005 femy:PlacementAgentWarrantsMember femy:August2025FinancingMember 2026-09-30 0001339005 femy:PlacementAgentWarrantsMember femy:August2025FinancingMember 2025-08-25 0001339005 femy:PreFundedWarrantsMember femy:August2025FinancingMember 2025-08-25 2025-08-25 0001339005 femy:CommonWarrantsMember femy:August2025FinancingMember 2025-08-25 2025-08-25 0001339005 femy:PreFundedWarrantsMember femy:August2025FinancingMember 2026-07-01 2026-09-30 0001339005 femy:PreFundedWarrantsMember femy:August2025FinancingMember 2026-01-01 2026-09-30 0001339005 femy:PreFundedWarrantsMember femy:August2025FinancingMember 2026-09-30 0001339005 femy:August2026FinancingMember 2026-08-07 2026-08-07 0001339005 femy:PreFundedWarrantsMember femy:August2026FinancingMember 2026-08-07 0001339005 femy:CommonWarrantsMember femy:August2026FinancingMember 2026-08-07 0001339005 femy:MilestoneWarrantsMember femy:August2026FinancingMember 2026-08-07 0001339005 femy:CommonWarrantsMember femy:August2026FinancingMember 2026-08-07 2026-08-07 0001339005 femy:MilestoneWarrantsMember femy:August2026FinancingMember 2026-08-07 2026-08-07 0001339005 femy:CommonWarrantsMember femy:August2026FinancingMember 2026-09-30 0001339005 femy:MilestoneWarrantsMember femy:August2026FinancingMember 2026-09-30 0001339005 femy:August2026FinancingMember 2026-08-07 0001339005 femy:August2026FinancingMember us-gaap:PrivatePlacementMember 2026-08-07 2026-08-07 0001339005 us-gaap:PrivatePlacementMember femy:August2026FinancingMember 2026-09-03 0001339005 femy:August2026FinancingMember 2026-09-03 0001339005 femy:PreFundedWarrantsMember femy:August2026FinancingMember 2026-08-07 2026-08-07 0001339005 femy:PreFundedWarrantsMember femy:August2026FinancingMember 2026-07-01 2026-09-30 0001339005 femy:PreFundedWarrantsMember femy:August2026FinancingMember 2026-01-01 2026-09-30 0001339005 femy:PreFundedWarrantsMember femy:August2026FinancingMember 2026-09-30 0001339005 femy:CommonWarrantsMember femy:August2025FinancingMember 2026-01-01 2026-09-30 0001339005 femy:UnderwriterWarrantsMember femy:August2025FinancingMember 2026-01-01 2026-09-30 0001339005 srt:MinimumMember femy:CommonWarrantsMember femy:August2025FinancingMember 2026-09-30 0001339005 srt:MaximumMember femy:CommonWarrantsMember femy:August2025FinancingMember 2026-09-30 0001339005 femy:UnderwriterWarrantsMember femy:August2025FinancingMember 2026-09-30 0001339005 femy:CommonWarrantsMember femy:August2026FinancingMember 2026-01-01 2026-09-30 0001339005 femy:MilestoneWarrantsMember femy:August2026FinancingMember 2026-01-01 2026-09-30 0001339005 femy:Two021StockOptionPlanMember 2026-09-30 0001339005 femy:InducementGrantMember 2026-01-01 2026-09-30 0001339005 femy:Two021StockOptionPlanMember 2026-01-01 2026-09-30 0001339005 us-gaap:EmployeeStockOptionMember 2026-09-30 0001339005 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-09-30 0001339005 us-gaap:RestrictedStockUnitsRSUMember 2026-09-30 0001339005 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-09-30 0001339005 femy:EmployeeStockPurchasePlanMember 2026-01-01 2026-09-30 0001339005 femy:EmployeeStockPurchasePlanMember 2026-09-30 0001339005 femy:Two021StockOptionPlanMember 2025-12-31 0001339005 femy:InducementGrantMember 2025-12-31 0001339005 femy:InducementGrantMember 2026-09-30 0001339005 femy:Two021StockOptionPlanMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2026-01-01 2026-09-30 0001339005 femy:InducementGrantMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2026-01-01 2026-09-30 0001339005 femy:Two021StockOptionPlanMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2026-01-01 2026-09-30 0001339005 us-gaap:RestrictedStockUnitsRSUMember 2025-12-31 0001339005 us-gaap:ResearchAndDevelopmentExpense 2026-07-01 2026-09-30 0001339005 us-gaap:ResearchAndDevelopmentExpense 2025-07-01 2025-09-30 0001339005 us-gaap:ResearchAndDevelopmentExpense 2026-01-01 2026-09-30 0001339005 us-gaap:ResearchAndDevelopmentExpense 2025-01-01 2025-09-30 0001339005 us-gaap:SellingAndMarketingExpense 2026-07-01 2026-09-30 0001339005 us-gaap:SellingAndMarketingExpense 2025-07-01 2025-09-30 0001339005 us-gaap:SellingAndMarketingExpense 2026-01-01 2026-09-30 0001339005 us-gaap:SellingAndMarketingExpense 2025-01-01 2025-09-30 0001339005 us-gaap:GeneralAndAdministrativeExpense 2026-07-01 2026-09-30 0001339005 us-gaap:GeneralAndAdministrativeExpense 2025-07-01 2025-09-30 0001339005 us-gaap:GeneralAndAdministrativeExpense 2026-01-01 2026-09-30 0001339005 us-gaap:GeneralAndAdministrativeExpense 2025-01-01 2025-09-30 0001339005 us-gaap:EmployeeStockOptionMember 2026-07-01 2026-09-30 0001339005 us-gaap:EmployeeStockOptionMember 2025-07-01 2025-09-30 0001339005 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-09-30 0001339005 femy:EmployeeStockPurchasePlanMember 2026-07-01 2026-09-30 0001339005 femy:EmployeeStockPurchasePlanMember 2025-07-01 2025-09-30 0001339005 femy:EmployeeStockPurchasePlanMember 2026-01-01 2026-09-30 0001339005 femy:EmployeeStockPurchasePlanMember 2025-01-01 2025-09-30 0001339005 us-gaap:RestrictedStockUnitsRSUMember 2026-07-01 2026-09-30 0001339005 us-gaap:RestrictedStockUnitsRSUMember 2025-07-01 2025-09-30 0001339005 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-09-30 0001339005 2023-11-01 2023-11-30 0001339005 femy:SeriesAWarrantsMember 2023-11-30 0001339005 femy:SeriesBWarrantsMember 2023-11-30 0001339005 femy:SeriesBWarrantsMember 2026-09-30 0001339005 us-gaap:CommonStockMember 2025-11-01 2025-11-30 0001339005 2025-11-01 2025-11-30 0001339005 femy:June2025FinancingMember femy:ExecutiveOfficerAndDirectorMember us-gaap:PrivatePlacementMember 2025-06-30 0001339005 femy:June2025FinancingMember femy:ExecutiveOfficerAndDirectorMember us-gaap:PrivatePlacementMember 2025-06-01 2025-06-30 0001339005 femy:OtherInvestorsMember femy:June2025FinancingMember 2025-06-30 0001339005 femy:June2025FinancingMember 2026-09-30 0001339005 srt:OfficerMember femy:CommonWarrantsMember femy:August2025FinancingMember 2025-08-31 0001339005 femy:CommonWarrantsMember femy:August2025FinancingMember 2025-08-31 0001339005 femy:August2025FinancingMember 2025-08-01 2025-08-31 0001339005 femy:August2025FinancingMember 2026-09-30 0001339005 femy:November2025FinancingMember femy:ExecutiveOfficerAndDirectorMember us-gaap:CommonStockMember 2025-11-30 0001339005 femy:November2025FinancingMember femy:SeriesA1WarrantsMember 2025-11-01 2025-11-30 0001339005 femy:November2025FinancingMember femy:SeriesB1WarrantsMember 2025-11-01 2025-11-30 0001339005 femy:November2025FinancingMember femy:SeriesC1WarrantsMember 2025-11-01 2025-11-30 0001339005 femy:November2025FinancingMember femy:SeriesD1WarrantsMember 2025-11-01 2025-11-30 0001339005 femy:November2025FinancingMember femy:SeriesD1WarrantsMember 2025-11-30 0001339005 femy:November2025FinancingMember femy:ExecutiveOfficerAndDirectorMember 2026-09-30 0001339005 srt:OfficerMember femy:August2026FinancingMember 2026-08-31 0001339005 srt:OfficerMember femy:CommonWarrantsMember femy:August2026FinancingMember 2026-08-31 0001339005 srt:OfficerMember femy:MilestoneWarrantsMember femy:August2026FinancingMember 2026-08-31 0001339005 femy:August2026FinancingMember 2026-08-31 0001339005 femy:August2026FinancingMember srt:OfficerMember 2026-08-01 2026-08-31 0001339005 femy:CommonWarrantsMember femy:August2026FinancingMember 2026-08-31 0001339005 femy:MilestoneWarrantsMember femy:August2026FinancingMember 2026-08-31 0001339005 femy:August2026FinancingMember 2026-09-30 0001339005 femy:WarrantsSixMember 2026-07-01 2026-09-30 0001339005 femy:WarrantsSixMember 2025-07-01 2025-09-30 0001339005 femy:WarrantsSixMember 2026-01-01 2026-09-30 0001339005 femy:WarrantsSixMember 2025-01-01 2025-09-30 0001339005 femy:WarrantsSevenMember 2026-07-01 2026-09-30 0001339005 femy:WarrantsSevenMember 2025-07-01 2025-09-30 0001339005 femy:WarrantsSevenMember 2026-01-01 2026-09-30 0001339005 femy:WarrantsSevenMember 2025-01-01 2025-09-30 0001339005 femy:WarrantsEightMember 2026-07-01 2026-09-30 0001339005 femy:WarrantsEightMember 2025-07-01 2025-09-30 0001339005 femy:WarrantsNineMember 2026-07-01 2026-09-30 0001339005 femy:WarrantsTenMember 2026-07-01 2026-09-30 0001339005 femy:WarrantsTenMember 2025-07-01 2025-09-30 0001339005 femy:WarrantsTenMember 2025-01-01 2025-09-30 0001339005 femy:WarrantsElevenMember 2025-07-01 2025-09-30 0001339005 femy:SingleReportableSegmentMember 2026-07-01 2026-09-30 0001339005 femy:SingleReportableSegmentMember 2025-07-01 2025-09-30 0001339005 femy:SingleReportableSegmentMember 2026-01-01 2026-09-30 0001339005 femy:SingleReportableSegmentMember 2025-01-01 2025-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure femy:Quarter femy:Segment

Keep reading